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ZUSAMMENFASSUNG 
„Murine double minute 2“ (Mdm2) ist eine E3-Ubiquitin-Ligase, die das Zellwachstum 
via Inhibition des Tumorsupressorproteins p53 fördert. Die Blockade dieses Enzyms 
durch das Kleinmolekül Nutlin-3a wird derzeit wegen seines potentiellen Nutzens in der 
Krebstherapie in klinischen Studien getestet. Die möglichen Nebenwirkungen von 
Nutlin-3a in gesunden Geweben, bedingt durch die Störung der Zellhomöostase auf 
Grund Konzentrationsverschiebungen zwischen p53 und Mdm2, geben jedoch Anlass 
zur Sorge. In einem acute-kidney-injury(AKI)-Mausmodell zeigte die Verabreichung von 
Nutlin-3a eine verminderte Heilungsfähigkeit. Zudem zeigte die spezifische Mdm2-
Deletion in Podozyten und Tubuluszellen eine signifikante Beeinträchtigung der 
Nierenfunktion, einhergehend mit der Einleitung von Podoptosis (p53-overexpression 
dependent cell death). Auf Grund dieser Beobachtungen stellten wir die Hypothese auf, 
dass die Gabe von Nutlin-3a in gesunden Mäusen die Nierenfunktion durch Podoptosis 
der Podozyten und Tubuluszellen schädigt. 
 
Im Einklang mit der Hypothese beobachteten wir durch die Stimulation von 
Mauspodozyten- und Maustubuluszell-Kulturen mit Nutlin-3a vermehrten 
Zelluntergang. Zudem verursachte die Nutlin-3a-Verabreichung in gesunden Mäusen 
die Stabilisierung von p53 mit resultierender Funktionsbeeinträchtigung der 
glomerulären Filtrationsbarriere und Albuminurie aufgrund einer Podocytopenie. Es 
konnte weiterhin eine vermehrte Makrophageninfiltration, eine Hochregulation von 
Markern der Tubulusschädigung und Entzündungsreaktion, sowie erhöhtes Blut-
Harnstoff-Stickstoff beobachtet werden. Bei der Planung einer Nutlin-3a-Therapie, 
muss deshalb eine potentielle Nierenschädigung nach Blockade von Mdm2 
Berücksichtigung finden. 
 
Da sich eine Mdm2-Blockade in chronischen Glomerulopathien durch die Inhibition der 
mitotischen Katastrophe auch positiv auswirken kann, stellten wir die Hypothse auf, 
dass Nutlin-3a die diabetischen Nephropathie verbessern kann, indem 
Entzündungsreaktion und die mitotische Katastrophe in Podozyten unterdrückt werden. 
Erwartungsgemäß zeigte sich nach Nutlin-3a Gabe in diabetischen Mäusen reduzierte 
Inflammation und Fibrose, aber die Schädigung von Podozyten war nicht vermindert 
Zusammenfassung 
  
vii  
und die Nierenfunktion dadurch nicht verbessert. Entgegen der ursprünglichen 
Annahme, wurde im Vergleich zu Plazebo eine schlechtere Nierenfunktion hinsichtlich 
Blut-Harnstoff-Stickstoff, als auch eine signifikantere Podozytopenie beobachtet. Diese 
unerwarteten Ergebnisse unterstützen jedoch eine neuere Arbeit in metabolomics und 
computational network analysis von Saito et al., in welcher Mdm2 als ein wichtiges 
heruntergeregeltes Protein bei diabetischer Nierenerkrankung aufgezeigt wurde. 
 
Zusammenfassend kann die therapeutische Mdm2-Blockade eine Schädigung der 
Nierenfunktion sowohl in Nierengesunden, als auch in Patienten mit diabetischen 
Nephropathien begünstigen. 
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SUMMARY 
Murine double minute 2 (Mdm2) is an E3 ubiquitin ligase that promotes cell growth 
through negative regulation of the tumour suppressor p53. Its blockade with the small 
molecule antagonist Nutlin-3a is currently tested on clinical trials for its potential benefit 
as cancer treatment. The crucial equilibrium between p53 and Mdm2 in the cell 
homeostasis raises however concern on the effect of this drug in healthy tissues. Its 
administration in a mouse AKI model showed a diminished capacity of healing and the 
specific deletion of Mdm2 in both podocytes and tubular cells induced p53-
overexpression dependent cell death (podoptosis). For this reason we hypothesized 
that the administration of Nutlin-3a to healthy mice damages renal function by 
promoting podoptosis in podocytes and tubular cells.  
 
Consistent with the hypothesis, we observed that stimulation with Nutlin-3a increased 
cell death in cultured mouse podocytes and tubular cells. In addition, treatment with 
Nutlin-3a caused in healthy mice stabilization of p53 levels and subsequent 
podocytopenia, promoting albuminuria and impaired glomerular filtration barrier. 
Moreover, increased macrophage infiltration was observed together with upregulation 
of inflammatory and tubular injury markers and augmented blood urea nitrogen levels. 
Therefore, renal damage after blockade of Mdm2 needs to be regarded when 
considering Nutlin-3a therapy.  
 
As blockade of Mdm2 can at the same time be beneficial in chronic glomerulopathies 
by inhibiting podocyte mitotic catastrophe, we hypothesized that Nutlin-3a could 
ameliorate diabetic nephropathy by preventing mitotic catastrophe and inhibiting 
inflammation; effect that has been previously observed in different disease models, 
where inflammation plays a central role in the pathogenesis. The administration of 
Nutlin-3a to diabetic mice did indeed decrease inflammation and fibrosis but it did not 
improve podocyte injury or renal function; contrary to the original hypothesis, increased 
podocytopenia and decreased renal function in terms of BUN compared to the placebo 
group. These results could further support a recent work on metabolomics and 
computational network analysis from Saito et al., where Mdm2 was revealed as a 
relevant downregulated protein in the diabetic kidney disease. 
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In conclusion, therapeutic Mdm2 blockade may hold the risk of damaging renal function 
in patients with no underlying kidney diseases and also in those with diabetic 
nephropathy.   
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1. INTRODUCTION 
 
1.1 Chronic kidney disease 
Chronic kidney disease (CKD) is a gradual and progressive loss of kidney function, caused 
by abnormalities of kidney structure or function present for 3 months or longer (Levey AS 
2012). Renal abnormalities include albuminuria (albumin/creatinine ratio >30mg/g), urine 
sediment abnormalities, electrolyte imbalance due to tubular disorders, histological 
abnormalities and decreased glomerular filtration rate (GFR) <60 ml/min/1,73m2 (KDIGO 
2012).  
 
CKD severity can be classified according to the GFR in five different stages (table 1) (Levey 
AS 2005). However, the inclusion of albuminuria and clinical diagnosis to the classification 
defines more precisely the severity of the disease and helps to predict the prognosis (figure 
1) (Levey AS 2011, KDIGO 2012). The need of kidney replacement therapy to ensure the 
survival of patients defines end-stage renal disease (ESRD), the most advanced form of 
CKD.  
 
Table 1. Severity of kidney disease.  
Stage Description GFR 
(ml/min/1,73m2) 
Related terms 
1 Kidney damage with 
normal or increase in GFR 
≥90 Albuminuria, proteinuria, 
haematuria 
2 Kidney damage with mild 
decrease in GFR 
60-89 Albuminuria, proteinuria, 
haematuria 
3 Moderate decrease in 
GFR 
30-59 Chronic renal insufficiency, early 
renal insufficiency 
4 Severe decrease in GFR 15-29 Chronic renal insufficiency, early 
renal insufficiency, pre-ESRD 
5 Kindey failure <15  
(or dialysis) 
Renal failure, uraemia, ESRD 
GFR = glomerular filtration rate; ESRD = End-stage renal disease. Adopted from (Levey AS 2005). 
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 Persistent albuminuria categories 
Description and range 
  
A1 A2 A3 
Normal to 
mildly 
increase 
Moderately 
increased 
Severely 
increased 
 <30mg/g 30-300mg/g >300mg/g 
G
FR
 
ca
te
go
rie
s 
(m
l/m
in
/1
,
73
m
2 ) 
G1 Normal or high >90    
G2 Mildly decreased 60-89    
G3a Mildly to moderately 
decreased 
45-59    
G3b Moderately to 
sevrely decreased 
30-44    
G4 Severely decreased 15-29    
G5 Kidney failure <15    
Figure 1. Prognosis of CKD by GFR and albuminuria categories. The colours represent the intensities of 
risk. Green: low risk; yellow: moderately increased risk; orange: high risk; red: very high risk. Adapted from 
(KDIGO 2012). 
 
The prevalence of CKD accounts for approximately 14% of the adult US population, being 
the main risk factors cardiovascular disease and diabetes mellitus, followed by hypertension 
and obesity (Levey AS 2010, USRDS 2015). The prevalence of CKD showed an increasing 
tendency in the nineties (Ju W 2012), but it stabilized in the last years mostly due to the 
reduction of percent of individuals at target blood pressures, percent of individuals not 
smoking and percentage of diabetics with glycosylated hemoglobin <7% (USRDS 2015). 
 
 
1.2 Diabetic kidney disease 
1.2.1 Diabetes Mellitus 
Diabetes mellitus (DM) refers to a group of common metabolic disorders that shares the 
phenotype of hyperglycemia (Powers AC 2008). According to the pathophysiological 
process that leads to hyperglycaemia, DM can be classified into different types (table 2) 
from which type 2 diabetes (T2D), involving around 90% of DM, and type 1 diabetes (T1D) 
are the most prevalent. While in T1D there is a total lack of insulin due to destruction of 
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pancreatic β cells, in T2D the pathophisiology combines peripheral insulin resistance, 
impaired insulin secretion and increased glucose production (Powers AC 2008). The 
aetiology of T1D and T2D combines both genetic predisposition with environmental factors. 
The environmental triggers of T1D in genetically predisposed individuals are not well 
known. In T2D, it has been shown that lifestyle habits contribute greatly to the development 
and progression of the disease, involving mainly high fat diet and physical inactivity 
(ECDCDM 2002).  
 
Table 2. Classification of diabetes types. 
Types of diabetes 
1.Type 1 diabetes 
A. Immune-mediated 
B. Idiopathic 
2. Type 2 diabetes 
3. Other specific types of diabetes 
A. Genetic defects of βcell function 
MODY 1 (hepatic nuclear transcription factor 4α, HNTF-4α) 
MODY 2 (glucokinase) 
MODY 3 (HNF 1α) 
MODY 4 (insulin promoter factor 1) 
MODY 5 (HNF 1β) 
MODY 6 (NeuroD1) 
Mithocondrial DNA  
Subunits of ATP-sensitive potassium channels 
Proinsulin or insulin conversion 
B. Genetic defects to insulin action: type A insulin resistance, Leprechaunism, Rabson-
Mendenhall syndrome, lipodystrophy syndromes 
C. Diseases of the exocrine pancreas: pancreatitis, pancreatectomy, neoplasia, cystic 
fibrosis, hemchromatosis, fibrocalculous pancreatopathy, mutations in carboxyl ester 
lipase 
D. Endocrinopathies: acromegaly, Cushing’s syndrome, glucagonoma, 
pheocromocytoma, hyperthirodism, somatostatinoma, aldosteronoma 
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E. Drug or chemical induced: vacor, pentamidine, nicotininc acid, glucocorticoids, thyrid 
hormone, diazoxide, βadrenergic agonists, thazides, phenytoin, α-interferon, protease 
inhibitors, clozapine. 
F. Infections: congenital rubella, cytomegalovirus, coxsackie 
G. Uncommon forms of immune-mediated diabetes: ‘stiff-person’ syndrome, anti insulin 
receptor antibodies. 
H. Other genetic syndromes sometimes associated with diabetes: Wolfram’s syndrome, 
Friedreich’s ataxia, Huntington’s chorea, Laurence Moon-Biedl syndrome, myotonic 
dystrophy, porphyria, Prader-Willi syndrome. 
4. Gestational diabetes mellitus (GDM) 
Adapted from (Powers 2008). 
The prevalence of DM worldwide was around 10% in 2013; that is 347 million people, of 
which 60 million are affected in Europe. By 2025, the number of people with diabetes is 
expected to increase and even to double in regions such as North Africa, Eastern 
Mediterranean and South-East Asia. Moreover, many countries are now reporting that the 
onset of type 2 diabetes in young people is also raising, due to increased sedentary 
lifestyles and obesity (WHO 2015). These figures imply a very high rate in morbidity and 
mortality: in 2013, around 5 million people died as a result of disease complications (WHO 
2015). Diabetic complications are generally classified in macrovascular and microvascular. 
Macrovascular complications comprise coronary artery disease, peripheral artery disease 
and cerebrovascular disease, whilst microvascular complications include retinopathy, 
neuropathy (sensory and motor and autonomic) and nephropathy.  
1.2.2 Diabetic kidney disease 
Diabetic kidney disease (DKD) is a microvascular complication of long-standing diabetes 
characterized by persistent albuminuria (>300mg/24h), declined GFR and elevated blood 
pressure (Alpers CE 2007). The natural history of DKD has been mostly studied in type 1 
diabetes (T1D), because the onset is usually evident and it occurs earlier in life, so the 
duration of diabetes is longer as for those with T2D.  Back in 1983 a conceptual division of 
the natural history of DKD was described by Mogensen. This one starts with a nephron 
hypertrophy and hyperfiltration, followed by a thickening of the glomerular basal membrane 
and the expansion of mesangial matrix. In later stages, microalbuminuria can be detected, 
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first isolated and then together with the decline of glomerular filtration rate (GFR), the 
augment of blood pressure and the presence of other diabetic complications such as 
retinopathy (Mogensen CE 1983). Microalbuminuria is therefore one of the major predictive 
factor for the development of DKD in diabetic patients (Wolf 2007). However, other factors 
like sex, age, glucose control, duration of diabetes, obesity, hypertension and other 
comorbidities, above all in T2D, play also a significant role in the progressive deterioration 
of kidney function (Atsuhito T 2005, Dong Z 2016). Therefore a more complex natural 
history than the one presented by Mogensen should be considered.  
 
1.2.3 Pathophysiology of diabetic kidney disease 
The increased glomerular filtration rate (GFR) at early stages of DKD has been recognized 
as a pivotal event in the progression of DKD since many years, but the pathomechanism 
behind was unclear. It had been related to impaired autoregulation and the activation of the 
local intrarrenal renin-angiotensin aldosterone system (RAAS), being its cause 
hyperglycaemia (Kanwar YS 2011). The link between these events was recently unveiled 
thanks to a new oral antidiabetic drug with renoprotective properties, Empagliflozin (see 
section 1.2.5 Current therapies), and is associated with correcting hyperreabsortion of 
sodium chloride in the proximal tubule and reinstalling a positive tubuloglomerular feedback 
(TGF) (Vallon V 2012). TGF is a mechanism of GFR regulation involving the macula densa, 
located at the end of the thick ascending limb, and the juxtaglomerular cells, located in the 
afferent arteriole. This regulation consists in keeping a constant filtration pressure despite 
variation in systemic blood pressure. If blood pressure increases, so does the filtration 
causing a higher sodium concentration in the tubular fluid. The macula densa senses this 
and releases adenosine, which provokes the vasoconstriction of the afferent arteriole and 
the inhibition of renin release from juxtaglomerular cells. The afferent vasoconstriction 
together with the efferent vasodilation, due to decreased Angiotensin II (ANGII), reduces the 
glomerular pressure and thus the single nephron GFR (SNGFR). In the opposite scenario, 
the decreased concentration of sodium in the macula densa activates renin release, leading 
to vasoconstriction of the efferent arteriole and therefore to a higher glomerular pressure 
and SNGFR (Vallon V 2010). 
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Figure 2. Hyperglycaemia and deactivation of the tubuloglomerular feedback (TGF). The increased 
reabsortion of glucose in the proximal tubule under hyperglycaemic conditions implies an increased reabsortion 
of sodium and therefore a reduced concentration of sodium in the distal tubule and the macula densa. This 
causes a release of renin from juxtaglomerular cells and a consequent activation of RAAS, which provokes 
efferent vasoconstriction and a higher glomerular pressure as well as higher SNGFR. SGLT2 = sodium glucose 
cotransporter-2, RAAS = Renin Angiotensin Aldosterone System, SNGFR= Single-Nephron glomerular filtration 
rate.  
 
The decreased sodium concentration in the macula densa can also be caused by an 
augmented reabsortion of sodium in the proximal tubule, like in diabetes. Sodium is 
cotransported with glucose in the proximal tubule trough SGLT2 and in the distal tubule 
trough SGLT1. Most of glucose reabsortion, around 97%, takes place in the proximal tubule 
(Vallon V 2015). In hyperglycaemic conditions the reabsortion of glucose increases up to 
two- to three-fold (Vallon V 2015) and implies for that reason a higher reabsortion of 
sodium, decreasing its concentration in the macula densa and deactivating the TGF (figure 
2). The higher reabsortion of glucose is not only linked to higher filtered glucose 
concentration but also to an upregulation of Sglt1 and Sglt2 genes and an overexpression 
of these cotransporters, as shown in Zucker rats and in in-vitro cultures of human exfoliated 
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proximal epithelial cells collected from T2D patients urine (Vestri S 2001, Vidotti DB 2008, 
Tabatabai NM 2009, Rahmoune H 2005).  
 
Hyperreabsortion of NaCl is additionally a consequence of the tubular growth observed in 
diabetic kidneys. The tubular growth involves in an early phase hyperplasia and later on 
hypertrophy (Vallon V 2012). Growth factors such as insulin-growth-factor 1 (IGF-1), 
vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) contribute 
greatly to the early tubular hyperplasia (Chiarelli F 2009). The overexpression of genes 
related to proliferation, like ornithine decarboxylase (ODC) (Satriano J 2006) or mammalian 
target of rapamycin complex 1 (mTORC1) (Lee MJ 2007), plays also a role. The 
upregulation of OCD follows the activation of protein kinase C (PKC), due to high glucose 
concentrations, and the activation of the JAK/STAT pathway through the generation of 
reactive oxygen species (ROS) in a diabetic milieu (Satriano J 2006).  
 
In a later stage, the kidney growth occurs through hypertrophy. This shift is mediated by 
TGF-β (Han DC 2000), induced also by the activated JAK/STAT pathway and PKC. At the 
same time the upregulation of the CKD inhibitors p21 and p27, promoted by TGF-β, ROS, 
PKC and JAK/STAT pathway, provokes a switch from proliferation to hypertrophy and 
eventually cell senescence (Huang JS 2007, Satriano J 2010, Vallon V 2012). 
 
 
 
Figure 3. Schematic drawing of the 
glomerular filtration barrier, 
composed of podocytes and its 
pseudopods, the glomerular 
basement membrane (GBM) and the 
endothelium. Adapted from 
(Haraldsson B. 2008).  
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Another important event in the natural history of DKD is the impairment of the glomerular 
filtration barrier (GFB) function and the leakage of plasma proteins, resulting in intermittent 
microalbuminuria at the beginning and permanent macroalbuminuria in later stages. Three 
layers compose the glomerular filtration barrier: fenestrated glomerular endothelium, a 
glomerular basement membrane (GBM) and a highly specialised epithelium: the podocytes 
(figure 3) (Haraldsson B. 2008). Despite many factors may contribute to the development of 
proteinuria, such as hemodynamic changes and mesangial expansion, many studies point 
at podocyte injury as the main causative event (Wolf G 2008). The loss of podocytes has 
been demonstrated to correlate with later development of proteinuria in normoalbuminuric 
diabetic patients (Dalla Vestra M 2003) and with the magnitude of proteinuria in those with 
DKD (White KE 2004). Accordingly, many studies presented that loss of nephrin, an 
important structural protein from the podocyte slit diaphragm, occurs in DKD patients (Pätäri 
A 2003, Benigni A 2004). The detailed molecular mechanisms leading to podocytopenia 
and loss of nephrin are not completely understood, but many studies using rodent models 
point towards ANGII as an important mediator, along with the vascular endothelial growth 
factor (VEGF) (Sung SH 2006, Ziyadeh FN 2008). Additionally, proteinuria itself could 
amplify podocyte injury further by a positive feedback cycle, since albumin, like 
hyperglycemia, induces the overexpression of TGFβ1 in podocytes (Ziyadeh 2004, 
Shankland 2006, Wolf G 2007). 
 
The albumin that is filtrated in the glomerulus can in the proximal tubule be reabsorbed by 
endocytosis (Birn H 2006), stimulated by ANGII (Caruso-Neves C 2005), which is 
synthesized not only in juxtaglomerular cells but also in tubular cells in high ambient 
glucose (Wei CC 2006). An increase in tubular albumin reabsorption will then activate the 
tubular RAAS leading to a vicious cycle (Wolf G 2004). Furthermore, tubular reuptake of 
albumin induces pro-inflammatory and profibrogenic cytokines (Ruiz-Ortega M 2006) and 
the recruitment of inflammatory cells in the glomerular and interstitial compartments 
(Navarro-González JF 2011). Together these processes contribute to inflammation, 
perpetuation of renal abnormalities, glomerulosclerosis and nephron loss. 
 
Inflammation is also a major driving force in the development of DKD. The activation of 
polyol and PKC pathway due to hyperglycaemia as well as the formation of advanced 
glycation end-products (AGE) and reactive oxygen species (ROS) trigger a cascade of 
Introduction 
9  
signalling events that promote and enhance inflammation (Yashpal S 2011). An example of 
it is the activation of the transcription factor NF-κB, which activates the release of 
proinflammatory cytokines such as TGF-β1, CCL2 (chemokine ligand 2) or ICAM1 
(intercellular adhesion molecule 1) (Ziyadeh FN 2008, Yang B 2008, Wada J 2013). Other 
cytokines critically involved in the diabetic nephropathy are IL-1, IL-6-and IL-18 (Navarro-
González JF 2011). 
 
In summary, hyperglycaemia activates a variety of pathways that promote hemodynamic 
changes, structural modifications, and inflammation (Wada J 2013), which further trigger the 
same or other pathways reinforcing this cycle and aggravating the disease. Still many other 
factors not yet well known play a role in the development of DKD, such as microRNAs 
(Hagiwara S 2013) or genetic predisposition. In fact, observational studies have shown that 
DKD occurs in familiar clustering and that there are important ethnical factors involved 
(García-García PM 2014).  
 
 
1.2.4 Mouse models of diabetes 
Many mouse models have been used to resemble the human pathology of diabetic 
nephropathy as a consequence of hyperglycaemia, but these models do not mimic the 
actual pathophysiology of the disease (Anders HJ 2016). For that reason, human translation 
is often difficult since a complex disease like diabetes, determined by multiple factors, 
involving both genetics and environment, is extremely difficult to imitate. The animal models 
so far developed can be broadly classified into spontaneous/congenital, diet-induced, 
chemical-induced, surgical and transgenic diabetic models (Wang B. 2014). The first ones 
are the most widely used and include the leptin and leptin receptor deficient models, which 
disrupt the leptin signaling pathway leading mainly to obesity and other metabolic 
disturbances. Leptin is produced mostly in the adipocytes and in a small proportion in the 
brown adipose tissue, skeletal muscle, placenta, ovaries, bone marrow and stomach. In the 
hypothalamus, leptin modulates food intake and energy expenditure. In peripheral tissues 
leptin also plays different roles involving energy homeostasis, skeletal growth, 
neuroprotection and oncogenesis (Moran O. 2003). While leptin deficient mice (ob/ob) carry 
a nonsense mutation on the obese gene (i.e. leptin encoding gene) that truncates the 
biologically active protein, leptin receptor deficient mice (db/db), on the other hand, have an 
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abnormal mRNA splicing of the Ob-Rb protein (i.e. leptin receptor isoform expressed mainly 
in the central nervous system) (Rees D.A. 2005). As a result of this spontaneous mutation, 
ob/ob mice develop early and severe obesity and hyperglycaemia, though mild and 
transient, until they are 3 months of age, when the glycemia goes back to normality, 
probably due to hyperinsulinemia. This compensatory hyperinsulinemia is a result of βcell 
hypertrophy and contributes to the obese phenotype. They display as well insulin resistance 
but do not develop (or they do poorly) macrovascular or microvascular complications. 
Contrasting with this phenotype, db/db mice do develop severe hyperglycaemia together 
with obesity, hyperinsulinemia, insulin resistance and eventually βcell dysfunction with no 
amyloid deposition. This scheme resembles a bit more the features of T2DM, albeit not 
mimic completely. Dyslipidemia is also present in this model but with high levels of HDL and 
low LDL, as opposed to humans. Macrovascular complications are generally not developed 
and in fact, arterial blood pressure and heart rates are reduced. Microvascular 
complications do faintly develop after some months, but incompletely (Wang B. 2014) (table 
3). 
 
Table 3 Manifestations of the db/db mouse model and its similarities and differences 
with human T2DM features. 
Human T2DM-like features Differences with human features 
Obesity Early-onset. Severe 
Hyperglycaemia Severe 
Insulin resistance  
Hyperinsulinemia and eventual βcell 
destruction 
No amyloid deposition 
Hyperlipidemia with ↑LDL and ↓HDL ↑HDL 
Development of microvascular 
complications 
Incomplete phenotype 
Normal or high blood pressure Reduced systemic arterial blood pressure 
 Depressed heart rate and basal systolic 
contraction 
Adapted from (Wang B. 2014). 
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1.2.5 Current therapies 
The basics of the DKD therapy is based on three pillars: a strict glycaemic control to stop 
changes triggered by a diabetic milieu, control of blood pressure to halt hemodynamic 
remodelling, and reduction of lipidemia to shrink inflammation (Gentile G 2014). First, a 
strict glycaemic control has been proved beneficial in many trials for both development and 
progression of DKD in T1D (DCCT 1993, EDIC 2003, DCCT/EDIC 2011) and T2D (UKPDS 
1998, ADVANCE 2008, Ismail-Beigi F 2010), although clinical benefits are weaker when 
complications are already present (Fullerton B 2014). In fact, a tight control entails a 
cardiovascular risk for subjects with long-standing diabetes (ACCORD 2008, Dluhy RG 
2008, Lachin 2010, Riddle 2010). 
 
Empagliflozin, an inhibitor of sodium-glucose transporter (SGLT)-2, is a new oral 
antidiabetic (OAD) that offers promising perspectives in the treatment of DKD, not only due 
to the glycaemic control, but also in the correction of the deactivation of tubuloglomerular 
feedback (TGF) that occurs in diabetes (see section 1.2.3 Pathophysiology of diabetic 
nephropathy).  By inhibiting SGLT-2, Empagliflozin decreases the reabsortion of glucose in 
the proximal tubule and promotes glucosuria and reduction of hyperglycaemia in an insulin-
independent manner (unlike other OAD) (Wanner C 2016). At the same time, thanks to the 
inhibition of glucose reabsortion in the proximal tubule, the cotransport of sodium is also 
inhibited, being then the tubular fluid sodium concentration in the macula densa higher. This 
reactivates the TGF and reduces the glomerular pression and SNGFR, thus contributing to 
reduce hyperfiltration and its deleterious effects in diabetic kidney disease (Vallon V 2015). 
Additionally, the inhibition of SGLT2 inhibits renal gluconeogenesis and by means of 
inducing glucosuria promotes weight loss and lower blood pressure, offering a lower rate of 
death from cardiovascular and death from any cause (Zinman B 2015). 
 
Second, lowering high blood pressure reduces CKD progression independently of 
proteinuria (Klag MJ 1996, Tozawa M 2003); therefore any drug that reduces blood 
pressure to less than 140/90 mmHg in non-proteinuric diabetic patient and less than 130/80 
in diabetic patients with DKD is recommended (NKF 2012). The recent SPRINT trial 
published in 2015 may even lower the target to less than 120, since it could be shown that 
in those patients with systolic blood pressure (SBP) <120mmH the primary outcome in 
terms of myocardial infarction, acute coronary syndrome, stroke, heart failure or death from 
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cardiovascular disease was less reported than in those with SBP < 140mmHg (SPRINT 
2015). However, the study did not include diabetic patients or patients at high risk of 
cardiovascular disease, reason why the study has raised some controversy (Grassi G 
2016). Nonetheless among all the antihypertensive drugs the ACE inhibitors have shown to 
have major benefit in DKD over the others. The reason: the inhibition of RAAS does not 
only control blood pressure but decreases also intraglomerular pressure and hyperfiltration, 
translating into reduced proteinuria (Ruggenenti P 2010). Moreover, the role of ANGII as 
mediator of pro-inflammatory pathways could also be inhibited (Ruiz-Ortega M 2006), thus 
contributing further to overall renoprotection.  
 
Third, lipid abnormalities, often found in diabetic patients (Jenkins AJ 2003), contribute to 
increase cardiovascular risk, albuminuria and CKD progression (Tolonen N 2009). Hence, 
treatment of hyperlipaedemia with statins has an important role in preventing cardiovascular 
outcomes. This could be shown in the SHARP trial, a randomised study comparing 
treatment with simvastatin plus ezetimibe and placebo, where the reduction of LDL 
cholesterol in patients with advanced chronic kidney disease reduced major atherosclerotic 
events (Baigent C 2011); however the intervention did not slow kidney disease progression 
in patients with chronic kidney disease (Haynes R 2014). Tonolo et al. nonetheless showed 
a slowed GFR decline in patients treated with simvastatine compared with cholestyramine, 
despite similar hypocholesterolemic effects (Tonolo G 2006), probably via attenuation of 
inflammatory effects and of oxidative stress.  
 
Meanwhile, novel drugs for DKD developed after the study of its pathophysiology have been 
tested: inhibitors of PKC, AGE/RAGE, NF-κB and JAK/STAT, antagonists of CCR2/CCR5 
or endothelin receptor or neutralizers of ICAM-1 (Gentile G 2014). An example of it is 
emapticap pegol, a RNA aptamer that aims to treat DKD by directly inhibiting CCL2 and 
reducing the activation and number of M2 macrophages, thus reducing tissue inflammation. 
In a phase IIa trial it improved the glycaemic control and significantly reduced the 
abumin/creatinin ratio, being safe and well tolerated. Moreover, those changes were 
maintained after cessation of the treatment, suggesting that emapticap pegol interferes with 
the underlying pathophisiology of DKD (Menne J 2016). Another promising drug targeting 
inflammation is CCX140-B, a CCR2 inhibitor that showed renoprotective effects in a phase 
III trial (de Zeeuw D 2015). Baricitinib is an inhibitor of JAK1/JAK2 that has been proved to 
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be effective in the treatment of rheumatoid arthritis and it is now being tested in a phase II 
randomized trial for DKD (Brosius FC 2015, O’Shea JJ 2013). CTP-499, a 
phosphodiesterase inhibitor, has been likewise recently tested in a phase IIA trial 
(Sabounjian L 2016, Perez-Gomez 2016). Another example is the compound Bardoxolone 
methyl, an activator of the Nrf2 pathway and inhibitor of the NF-κB pathway that reduces 
oxidative stress and inflammation. In the phase II clinical trial BEAM 227 patients with 
advanced CKD (eGFR between 20 and 45 ml/min/1,73cm2) were included and followed for 
24 weeks after Bardoxolone methyl or placebo administration. The first one showed an 
average increase of eGFR of 10ml/min/1,73cm2, whereas no changes were observed in the 
placebo group. In October 2011 the BEACON study (phase III trial) was started with 1600 
patients with CKD Stadium 4 and DKD. The study however had to be stopped after one 
year due to the higher cardiovascular events and overall mortality compared with the 
placebo line, probably due to fluid retention (de Zeeuw D 2013). For this work, Nutlin-3a, 
also an inhibitor of NF-κB pathway, has been proposed as a drug for DKD due to its anti-
inflammatory effect and to its protective role in stressed podocytes. 
 
 
1.3 Mdm2 blockade with Nutlin-3a and its potential as cancer therapy 
Nutlin-3a is a cis-imadazolin that competitively inhibits Mdm2 and prevents its interaction 
with the tumour suppressor p53, thus stabilizing its levels and blocking tumour growth in 
several animal models (Shangary S 2009). Therefore, Nutlin-3a has emerged as a 
promising therapy for cancer and a clinical trial in humans with advanced malignancies 
except for leukaemia has already been completed and a new one with leukaemia is 
currently ongoing1. 
 
1.3.1 Mdm2 and p53 
The gene Mdm2 was first identified in 1987 at the Howard Hughes Medical Institute in 
Pennsylvenia among two other genes, Mdm1 and Mdm3, in a spontaneously transformed 
mouse BALB/c cell line (3T3DM). The name Mdm stands for Murine double minute, as 
these three genes were located in small, acentromeric, extrachromosomal nuclear bodies 
called ‘double minutes’ , which have been stably maintained during long term growth of the 
3T3DM cells because it provides them with growth advantage (Cahilly-Snyder L 1987). In a                                                            1 www.clinicaltrials.gov RO5503781. 
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posterior work, the tumorigenic nature of Mdm2 and its product was proved by injecting 
non-transformed NIH3T32 cells transfected with Mdm2 in nude mice3, which caused the 
development of tumours at the site of injection (Fakharzadeh SS 1991). 
 
Simultaneously the group of Arnold Levine in Princeton worked on the same topic with the 
tumour suppressor p53. They observed in different cell lines and with different antibodies 
that p53 always coprecipitates with a protein with a molecular weight of 90kDa – they 
named it p90. Subsequently, they identified p90 as the product of Mdm2 (Momand J 1992) 
and its role as negative regulator of the tumour suppressor p53.  
 
The regulation of Mdm2 upon p53 was further disclosed with Mdm2 and Mdm2/p53 knock-
out mice germlines. The homozygous deletion of Mdm2 resulted in lethality at an early 
stage in embryonic development due to enhanced cell death. This phenotype was 
completely rescued using double Mdm2/p53 knock-out mice (Jones SN 1995, Montes de 
Oca Luna R 1995). Hence it was proved that Mdm2 negatively regulates p53 and prevents 
p53-dependent cell death.  
 
 
1.3.2 The p53-MDM2 regulatory loop 
Mdm2 is the main regulator of p53. Although p53 can be degraded in a Mdm2-independent 
manner, via MDMX and probably through other E3 ubiquitin ligases, like Cop1, Pirh2, ARF-
BP1, Topors, CAPPs or Synoviolin, the low efficiency of this process shows the importance 
of Mdm2 for such purpose (Clegg HV 2008, Marine JC 2010).                                                             2 NIH 3T3 mouse embryonic fibroblast cells come from a cell line isolated and initiated in 1962 at the New York University School of Medicine Department of Pathology. 3T3 refers to the cell transfer and inoculation protocol for the line, and means “3-day transfer, inoculum 3 x 10^5 cells.” Using this protocol, the immortal cell line begins to thrive and stabilize in cell culture after about 20-30 generations of in vitro growth. George Todaro and Howard Green, the scientists who first cultured this cell line, obtained the cells from desegregated NIH Swiss mouse embryo fibroblasts. The cell line has since become a standard fibroblast cell line. 3 Athymic mice.  
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Figure 4. Autorregulatory feedback loop. In conditions of no stress, Mdm2 inhibits p53 in three ways: 1) 
blocks transactivation of p53, 2) favours nuclear export, and 3) induces p53 degradation. However, upon DNA 
damage, p53 levels increase and transactivation of p53 targets takes place. Among p53 target genes, there is 
Mdm2. If the DNA damage is repaired, the increasing levels of Mdm2 will again inhibit p53 and restore its levels. 
Adapted from (Chène 2003).  
 
Mdm2 negative p53 regulation is achieved through three mechanisms (figure 4). First, 
Mdm2 hinders p53 to promote transcription by competing with its transcriptional machinery 
(Momand J 1992, Chen J 1993, Oliner JD 1993, Haupt Y 1997). Second, Mdm2 exports 
p53 from the nucleus to the cytoplasm, hence hampering further p53-dependent 
transcription (Roth J 1998). Third, by means of E3 ligase activity Mdm2 mediates 
ubiquitination of p53 promoting its proteasomal degradation (Haupt Y 1997, Honda R 1997, 
Kubbutat MH 1997). At the same time, p53 induces among other genes the transcription of 
Mdm2, establishing a negative feedback loop that further regulates levels of both proteins 
(Barak Y 1993, Perry ME 1993).  
 
Interestingly, Mdm2 can also promote p53 translation by interacting with p53 mRNA, while 
Mdm2 E3 ligase activity would be inhibited. Once the p53-Mdm2 protein complex is 
released from the polysome, Mdm2 ubiquitin ligase activity is released (Yin Y 2002, 
Candeias MM 2008, Naski N 2009). That proves further how the equilibrium of these two 
proteins is tightly regulated through several mechanisms that have evolved over time.  
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1.3.3 Mdm2 protein domains 
Mdm2 has several domains that are conserved among species (figure 5). The first of these 
domains in the aminoterminal region is the binding site of p53, which binds to the 
aminoterminal region of p53 (Chène 2003, Iwakuma T 2003, Zhao Y 2014). In this domain, 
Mdm2 forms a deep hydrophobic cleft, where p53 fits with mainly three side chains: Phe19, 
Trp23 and Leu26 (Chène 2003, Vassilev LT 2004). Mdm2 also possesses a conserved 
nuclear localization sequence (NLS) and a conserved nuclear export signal (NES) that 
mediate its ability to shuttle between the nucleus and the cytoplasm (Roth J 1998, D. A. 
Freedman 1999). This ability to commute between nucleus and cytoplasm was thought to 
be the means with which Mdm2 carries p53 out of the nucleus. However, Stommel et al 
asserted that the nuclear export of p53 was independent of Mdm2’s NES (Stommel JM 
1999). Yet Mdm2 may still contribute to the nuclear export with another conserved domain: 
the RING finger domain with E3 ubiquitin ligase activity (Geyer RK 2000).  
 
In addition, the RING finger domain promotes p53 proteasomal degradation (Haupt Y 1997, 
Honda R 1997, Kubbutat MH 1997). This domain in the carboxi-terminus of Mdm2 can 
catalyse p53 monoubiquitinitation, and thereby promote nuclear export, or p53 
polyubiquitination, and with it trigger proteasomal degradation. Whether the action is one or 
the other depends on p53 levels: in nonstressed cells, where p53 levels are low, E3 ligase 
induces monoubiquitination to keep the transcription factor out of the site of action and thus 
controls its response. But in stressed cells, where p53 levels are increased, the RING finger 
domain drives polyubiquitination to better control overexpression of the tumour suppressor 
(Li M 2003). Moreover, via the RING finger domain, Mdm2 can also ubiquitin itself and 
induce its own degradation, further commanding the regulatory mechanism that titrates 
precisely the levels of Mdm2 and p53 (Fang S 2000, Honda R 2000). Other authors 
however discuss that Mdm2 does not drive its own degradation, but other E3 ubiquitin 
ligases such us PCAF do (p300-CBP-associated factor) (Linares LK 2007, Clegg HV 2008). 
 
Figure 5. Mdm2 protein domains. The conserved domains of Mdm2 are the p53 interaction domain in the 
aminoterminus, the nuclear localization signal (NLS) and the nuclear export signal (NES), the acidic domain and 
Zinc finger, which interact with ribosomal proteins, and in the carboxiterminus the RING finger domain with E3 
ubiquitin ligase activity. Adapted from (Iwakuma T 2003). 
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1. p53 mutation or loss of function. This is seen in almost 50% of all tumours (Hainaut 
P 2000), highlighting the importance of p53 as guardian of the genome.  
2. Gain of function of Mdm2 via amplification of the gene, increase transcription or 
overexpression. This process is found in numerous types of tumors, such us 
sarcomas, glioblastomas, leukaemias, lymphomas and breast carcinoma and 
malignant melanomas, as well as in cancer-prone family syndromes (Reifenberger 
G 1993, Watanabe T 1994, Bueso-Ramos CE 1995, Poremba C 1995, Bueso-
Ramos CE 1996, Picksley SM 1996). 
3. Mdm2 gain of function coupled with p53 loss-of-function (Watanabe T 1994). This 
apparent redundancy suggests that Mdm2 has other oncogenic properties, 
independent of p53. (Jones SN 1998, Iwakuma T 2003). 
 
For this reason, to restore p53 wild type levels is a promising strategy in the treatment of 
several tumours (Li Q 2014). 
 
 
1.3.5 Mdm2 inhibitors and Nutlin-3a 
Two classes of Mdm2 inhibitors have been developed: peptide inhibitors and low molecular 
weight compounds. While the first inhibitors mimic p53 structure, the second compounds 
were developed with computational tools (Chène 2003, Shangary S. 2009). Among this last 
group cis-imadazolines, benzodiazepins and spiro-oxindoles have been studied. The cis-
imadazolines, named Nutlin, are the first reported inhibitors with a good interaction with p53 
(Patel S 2008). Among them, Nutlin-3, a racemic mixture of Nutlin-3a (active enantiomer) 
and Nutlin-3b (inactive enantiomer), has shown excellent pharmacokinetic properties: rapid 
absorption, high bioavailabitlity and saturable elimination kinetics (Vassilev LT 2004, Zhang 
F 2011). 
 
The interaction between Mdm2 and p53 can also be inhibited with HLI98, a compound that 
binds Mdm2 non-competitive and inhibits the E3 ligase activity, and RITA (reactivation of 
p53 and induction of tumour cell apoptosis), which binds p53 instead of Mdm2, thus 
inhibiting the interaction between these two partners as well (Marine JC 2010) (figure 7). 
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Figure 8. Inhibitors of the Mdm2-p53 interaction. Schematic representation of the Mdm2 and p53 proteins. 
Nutlin binds Mdm2 in the p53 binding domain in the aminoterminus, HLI98 binds Mdm2 in the RING domain, 
and RITA binds p53 in the transactivation domain.  Adapted from (Marine JC 2010). 
 
 
Despite sharing the same goal, all these inhibitors differ on the target, which might bestow 
each of them with particular features. For example, small molecules binding Mdm2 might 
inhibit not only p53-dependent but also p53-independent activities (Marine JC 2010), as it 
has already been shown with Nutlin-3a (see section below 1.4.2 P53-independent roles of 
Mdm2). And the other way around: inhibiting the interaction of p53 and Mdm2 by binding 
p53, stabilizes Mdm2 and promotes p53-independent activities, like the ubiquitination of 
hnRNPk. This promotes proteasomal degradation and prevents this protein to induce p21 
transactivation. The result of this is an induction of proapoptotic genes and cell death 
instead of cell cycle arrest (Eischen CM 2009). These differences might be therefore of 
advantage when treating different pathologies and aiming different goals. 
 
 
1.4 Nutlin-3a in previous studies of kidney disease 
1.4.1 Nutlin-3a in acute kidney injury (AKI) 
The role of Nutlin-3a in blocking Mdm2 and interfering with proliferation raised rapidly 
concern over a negative effect of this drug upon tissue regeneration. Mulay et al. 
approached this question with a murine model of acute kidney injury (AKI). They observed 
that in the kidney, Mdm2 is mainly expressed in tubular cells and that Mdm2 levels in these 
cells raise after 5 days of ischemia-reperfusion injury (Mulay SR 2012), coinciding with the 
regeneration phase. In an earlier phase of damage, however, p53 levels are elevated in 
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parenchymal cells (Kelly KJ 2003, Molitoris BA 2009). Surely, these observations were to 
be expected. After injury, damaged cells initiate a program through p53 of either repair or 
death depending on the severity. In a later phase, Mdm2 levels augment induced by high 
levels of p53 and inhibit further cell death whilst proliferation and regeneration are 
promoted.  
 
For that reason, Mulay et al revealed that inhibiting Mdm2 after renal ischemia-reperfusion 
injury leads to a worse outcome 5 days post-AKI, with increased TUNEL positive tubular 
cells compared to control (Mulay SR 2012). These results were consistent with other 
studies, such as the work of Gannon et al, where Mdm2 deletion in skin epithelium resulted 
in increased cellular senescence and impaired wound healing (Gannon HS 2011). 
 
Nonetheless, in this study a positive effect of Nutllin-3a was observed during an early 
phase, one day after AKI. This unexpected result could be reproduced in p53 knock-out 
mice, revealing a p53-independent effect of Mdm2. 
 
In this regard, Mulay et al performed another study about rapidly progressive 
glomerulonephritis (RPGN). Here the pre-emptive and delayed onset blockade of Mdm2 
with Nutlin-3a ameliorated the outcome of mice with crescentic glomerulonephritis 7 days 
after sheep GBM antiserum injection in terms of serum creatinine levels, blood urea 
nitrogen (BUN), albuminuria and neutrophil and macrophage recruitment. This effect was 
shown to be mostly p53-independent, since the same results were observed in p53-
knockout mice. The inhibition of parietal epithelial cells (PEC) hyperplasia was however 
p53-dependent. Together, it could be shown that Mdm2 drives inflammation in 
glomerulonephritis in a p53-independent way and PEC proliferation in a p53-dependent 
way; being its inhibition with Nutlin-3a a promising therapeutic strategy (Mulay SR 2016). 
 
 
1.4.2 P53-independent roles of Mdm2 
As introduced above, the work by Mulay and colleagues revealed a p53-independent role of 
Mdm2 on tissue inflammation that was later confirmed in vitro: Mdm2 facilitates the binding 
of nuclear factor κB (NFκB) to DNA (McNicholas BA 2012, Mulay SR 2012, Thomasova D. 
2012). This finding was consistent with the report of Hashimoto et al. showing that Mdm2 
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1.4.3 Nutlin-3a administration in mouse chronic kidney disease (CKD) models 
The antiinflammatory effect of Nutlin-3a was also observed in a CKD model of lupus 
nephritis (Allam R 2011). In this study the administration of Nutlin-3a to MRL-Fas(lpr) mice 
(a mouse model of lupus) showed a beneficial effect on preventing nephritis and lung 
disease by reducing systemic inflammation and abnormal proliferation of T-cells (Allam R 
2011). 
 
The role of Mdm2 and its blockade with Nultin-3a has been also studied in a mouse 
adriamycin model that causes progressive glomerulosclerosis, a process that accounts for 
the vast majority of chronic kidney disease (CKD) cases. It was expected, that 
administration of Nutlin-3a would worsen CKD by enhancing podocyte cell death, since 
Mdm2 is strongly expressed in podocytes inside the glomerulus (figure 8). Interestingly, 
renal function and podocyte survival improved significantly after blockade of Mdm2 owing to 
less mitotic catastrophe (Mulay SR 2013). Mitotic catastrophe is a type of cell death 
characterized by an aberrant chromosome segregation that leads to death immediately after 
mitosis or shortly after via programmed cell death or necrosis (Castedo M 2004). In 
differentiated podocytes, such aberrant chromosome segregation occurs because mitosis 
requires a complete reorganization of the actin cytoskeleton, which is not compatible with 
maintaining secondary foot processes and the slit membrane (L Lasagni 2013). Mdm2 
inhibits the p53 dependent cell cycle arrest and allows podocytes to override the cell cycle 
restriction point and complete aberrant mitosis leading to cell death (figure 9) (L Lasagni 
2013, Mulay SR 2013). 
 
In DKD, podocyte injury is also a major event in the progression of the disease, although 
the mechanisms of injury are not well known (see section 1.2.3 Pathophysiology of diabetic 
nephropathy). Nutlin-3a could be a novel approach to hamper podocyte injury and to 
diminish inflammation, thus protecting the kidney from disease progression.  
 
1.4.4 Toxicity of Nutlin-3a in kidney tissue 
Although sufficient evidence exists suggesting that transformed cells are more sensitive to 
p53-induced apoptosis than their normal counterparts, the observed p53-dependent 
pathologies after Mdm2 loss raise concern of the toxicity of small molecule inhibitors of 
Mdm2-p53 upon healthy tissues (Marine JC 2010).  
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Figure 9. Schematic diaphragm of podocytopathies and mitotic catastrophe. Podocyte stress activates 
podocytes to undergo hypertrophy to compensate podocytopenia. Hypertrophy takes place because of p53-
mediated induction of cyclin kinases such as p21, which arrest cell cycle in the G1 restriction point. Mdm2 
inactivates p53 and its targets and drives the podocyte to complete (aberrant) mitosis, resulting in bi- or 
multinucleated podocytes. As a consequence, aneuploid podocytes undergo immediately cell death and detach 
from the GFB or remain for some time in the GFB and then die. Adapted from (L Lasagni 2013). 
 
To illustrate this, in mice lacking Mdm2 and p53 the restoration of p53 for only ~24 hours 
initiated an ineluctable pathology leading to death within 5-6 days (Ringshausen I 2006). 
Profound body weight, diarrhoea and severe aplastic anaemia were observed, ascribed to 
death of radiosensitive organs such as bone marrow and intestine. Other tissues also 
displayed overexpression of p53 and exhibited cell proliferation inhibition, but in low-
replicating tissues, the effects of p53-mediated growth arrest would take a long time to be 
manifested. However, specific deletion of Mdm2 can show individual outcomes in each 
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tissue. For instance, selective deletion of Mdm2 in cardiomyocytes resulted in heart failure 
at E13.5 (Grier JD 2006), or selective deletion of Mdm2 in osteoblasts engendered mice 
that died at birth with multiple skeletal defects (Lengner CJ 2006). 
 
In renal tissue, the relevance of Mdm2 in podocyte homeostasis was highlighted by 
Thomasova et al. in resting podocytes both in vitro and in vivo. In vitro, deletion of Mdm2 
with siRNA caused an overexpression of p53 and cell death (Thomasova D. 2015). So far, 
p53 overexpression-dependent cell death – a process named by Thomasova et al as 
“podoptosis”- was assumed to be apoptosis in the literature, since p53 induces numerous 
apoptosis-related genes (Aylon Y 2007, Valentin-Vega YA 2008). Yet, in this study they 
observed that podoptosis does not imply caspase activation, therefore podocytes die not via 
apoptotic cell death. Other types of cell death including pyroptosis, pyronecrosis, 
necroptosis, ferroptosis and parthanatos were also excluded as modes of cell death 
(Ebrahim M 2015, Thomasova D. 2015).  
 
Accordingly, Mdm2 knockdown caused podocyte loss and proteinuria in a zebrafish model 
and in a podocyte-specific Mdm2-knockout mouse model, where the same abnormalities 
were observed along with progressive glomerulosclerosis. The phenotype of both animals 
was rescued with co-deletion of p53, further revealing the role of Mdm2 in maintaining 
homeostasis and long-term survival in podocytes (Thomasova D. 2015).  
 
These studies remark the risk of inhibiting Mdm2 in healthy tissues. Nonetheless, the use of 
small molecules to inhibit Mdm2 cannot be compared to genetic ablation, as they have a 
limited half-time. Hence it might be possible to find a therapeutic window.  
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2. HYPOTHESES 
Based on the above literature, the two following hypothesis were formulated: 
 
• Inhibition of Mdm2 with the small molecule Nutlin-3a damages renal function 
by promoting p53-overexpression dependent cell death (podoptosis) in 
podocytes and tubular cells.  
 
Previous work in our laboratory has shown that specific deletion of Mdm2 in both podocytes 
(Thomasova D. 2015) and tubular cells (data not yet published) triggers overexpression of 
p53 and cell death. In both cases, the structural and functional changes of these 
compartments led to CKD. Consistently, we hypothesized that the administration of Nutlin-
3a, a small molecule that inhibits the interaction of p53 and Mdm2, damages both 
podocytes and tubular cells in vitro and in vivo in a similar manner. 
 
 
• Inhibition of Mdm2 with Nutlin-3a ameliorates diabetic kidney disease via 
attenuation of inflammation and prevention of podocyte mitotic catastrophe.  
 
In a CKD mouse model with adriamycin and FSGS (focal segmental glomerulosclerosis) 
was revealed that rather than promoting cell death, inhibition of Mdm2 with Nutlin-3a in a 
context of podocyte stress protected them from mitotic catastrophe and improved the 
outcome (Mulay SR 2013) In addition, Nutlin-3a displayed beneficial effects in an 
inflammatory milieu after acute kidney injury (AKI) by inhibiting the transcription factor NFκB 
in a p53-independent manner (Mulay SR 2012). 
 
For that reason, we hypothesized that inhibition of Mdm2 with Nutlin-3a in diabetic kidney 
injury slows down the progression of the disease protecting podocytes from death via 
mitotic catastrophe and decreasing inflammation.  
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3. MATERIALS AND METHODS 
 
3.1 Materials 
3.1.1 Instruments 
Anaesthesia 
Isofluorane anaesthesia chamber   Harvard Anaesthesia system, UK 
 
Balances 
Analytic balance, BP110S    Sartorius, Göttingen, Germany 
Mettler PJ 300     Mettler-Toeldo, Greifensee, Switzerland 
 
Cell culture incubators 
Type B5060 EC-CO2     Heraeus Sepatech, München, Germany 
 
Centrifuges 
Heraeus, Minifuge T     VWR International, Darmstadt, Germany 
Heraeus, Biofuge primo   Kendro Laboratory Products, Hanau, Germany 
Heraeus, Sepatech Biofuge A   Heraeus Sepatech, München, Germany 
 
ELISA Reader 
Tecan, GENious Plus    Tecan, Crailsheim, Germany 
 
Microscopes 
Olympus DC 300F     Leica Microsystems, Cambridge, UK 
Leica DC 300F     Leica Mycrosystems, Cambridge, UK 
 
Real time PCR 
Light cycler 480     Roche, Germany 
 
Other equipment 
Glucometer accu check sensor   Roche, Manheim, Germany 
Homogenizer ULTRA-TURRAX T25  IKA GmbH, Staufen, Germany 
Nanodrop     PEQLAB Biotechnology, Erlangen, Germany 
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pH meter WTW     WTW GmbH, Weilheim, Germany 
Vortex Genie 2TM     Bender&Hobein AG, Zurich, Switzerland 
Water nath HI 1210    Leica Mycrosystems, Bensheim, Germany 
Neddles      BD Drogheda, Ireland 
Pipette’s tips 1-100ul     Eppendorf, Hamburg, Germany 
Plastic histocasettes     NeoLab, Heidelberg, Germany 
Syringes     Becton Dickinson GmbH, Heidelberg, Germany 
Tissue culture dishes 100x20mm   TPP, Trasadingen, Switzerland 
Tissue culture 96 well-plates   TPP, Trasadingen, Switzerland 
Tissue culture 6-well plates    TPP, Trasadingen, Switzerland 
Tubes 1.5, 2, 15, 50ml    TPP, Trasadingen, Switzerland 
Water bath HI 1210     Leica microsystems, Bensheim, Germany 
Pure Link RNA mini kit Ambion   LifeTechnologies, Carlsbad, CA, USA 
RT-PCR primers     Metabion, Martinsried, Germany 
 
Cell culture 
RPMI-1640 medium     GIBCO/Invitrogen, Paisley, Scotland, UK 
DMEM-medium     Biochron KG, Berlin, Germany 
Dulbecco’s PBS (1x)    PAA Laboratories GmbH, Cölbe, Germany 
FSC      Biochrom KG, Berlin, Germany 
Penicillin/Streptomycin (100x)  PAA Laboratories GmbH, Cölbe, Germany 
Trypsin/EDTA (1x)    PAA Laboratories GmbH, Cölbe, Germany 
 
3.1.2 Reagents 
Antibodies 
Mac2       Cederlane, Ontario, Canada 
TNFα       Abcam, Cambridge, UK 
Col 1       Abcam, Cambridge, UK 
p53       Santa Cruz Biotechnology, Santa Cruz, CA 
Wt1       Santa Cruz Biotechnologies, Santa Cruz, CA 
Nephrin      Acris Antibodies GmbH, Herford, Germany 
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ELISA and colorimetric assays 
Albumin      Bethyl Laboratories, TX, USA 
Creatinine FS     Diasys Diagnostic System, Holzheim, Germany 
Urea FS     Diasys Diagnostic System, Holzheim, Germany 
Cholesterol FS    Diasys Diagnostic System, Holzheim, Germany 
Triglycerides FS    Diasys Diagnostic System, Holzheim, Germany 
Cytotoxicity Detection Kit (LDH)   Roche, Basel, Switzerland 
Cell Titer Proliferation Assay   Promega, Madison, WI, USA 
 
3.1.3 Chemicals 
Acrylamide 30%     Carl Roth GmbH, Karlsruhe, Germany 
Beta-mercapto ethanol    Roth, Karlsruhe, Germany 
Bovine Serum Albumin    Roche Diagnostics, Manheim, Germany 
DMSO      Merck, Darmstadt, Germany 
Eosin       Sigma, Deisenhofen, Germany 
Ethanol      Merck, Darmstadt, Germany 
Formalin      Merck, Darmstadt, Germany 
Hcl (5N)      Merck, Darmstadt, Germany 
Isopraponolol      Merck, Darmstadt, Germany 
Sodium chloride     Merck, Darmstadt, Germany 
Sodium citrate     Merck, Darmstadt, Germany 
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3.2 Methods 
3.2.1 Animal studies 
Male wild type C57BL/6J mice from Charles River (Sulzeld, Germany) and male diabetic 
C57BLKS db/db mice from Taconic (Ry, Denmark) were purchased and housed in filter top 
cages with a 12 hours dark/light cycle. All animals had unlimited access to food and water 
throughout the study duration, except for the four hours previous to glucose measurement 
(see below in Glucose measurement). All animal experiments were approved by the local 
government authorities. 
 
 
Study design 
Wild type mice (C57B/6J) were purchased at the age of 15 weeks, except 5 mice  that were 
purchased at an age of 6 weeks-old, as baseline (control). All mice were treated with Nutlin-
3a on alternative days from week 16th until week 19th for a total of 4 weeks and sacrificed at 
the end of the treatment (week 20). Nutlin-3a (Selleckchen, USA) was administered in 
alternative days intraperitoneally (i.p.) at a dose of 20mg/kg diluted in 50% Dimethyl-
sulfoxide (DMSO). For the vehicle group, DMSO was injected i.p. with an equal 
concentration and amount (figure 10). A control group was kept separately with no 
intervention to rule out any independent renal or systemic effect of DMSO. 
 
 
Figure 10 Experimental time line of the animal study.  
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Diabetic mice (BKS.Cg-m+/+Leprdb/BomTac) were purchased at the age of six weeks and 
uninephrectomy was performed one week after, as described below inSurgical procedure of 
uninephrectomy and post-surgical care. When mice reached 10 weeks of age, chow diet 
was shifted to high fat diet till the end of the study to aggravate the phenotype (table 4 and 
5). Nutlin-3a at a concentration of 20mg/kg (diluted in 50% DMSO) or 50% DMSO only was 
administered i.p. for four weeks, starting from week 16 until 19 on alternative days (figure 
10).   
 
 
Table 4. High fat diet composition. Composition of the high fat diet (%), which was used 
to feed mice within the study. 
 
 
 
  
High fat diet  
Casein 24,00% 
Corn starch, pre-gelatinized 43,42% 
Maltodextrin 4,00% 
Sucrose 5,00% 
Cellulose powder 6,00% 
L-Cystine 0,30% 
Vitamins 1,00% 
Mineral & trace elements 6,00% 
Choline Cl 0,28% 
Pork lard 9,00% 
Soybean oil 1,00% 
Cholesterol ~67mg/kg 
Σ 100,00% 
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Table 5. Comparison between regular and high fat diet. 
 Unit Regular feed  
(chow diet) 
High fat diet 
Crude protein % 22,0 21,1 
Crude fat % 4,5 10,1 
Crude fiber % 3,9 5,7 
Crude ash % 6,8 5,3 
Starch % 34,0 41,7 
Sugar % 5,0 6,0 
Dextrins % - 4,0 
ME (Atwater) % 13,6 16,2 
Fat Kcal% 11 23 
ME = metabolizable energy 
 
Surgical procedure of uninephrectomy and post-surgical care 
Uninephrectomy was performed under general anaesthesia in a sterile environment. All 
instruments were sterilized through high temperatures (121ºC). Anaesthesia was 
administered intraperitoneally. Anaesthetised mice with no pain 
reflexes were positioned in right lateral decubitus on a sterile 
operation bed. Shaving of the surgical area was performed 
followed by disinfection of the skin with povidone iodide. To 
minimize surgical site contamination, the mouse was then 
covered with a sterile sheet –without obstructing breathing- 
leaving only exposed the area to operate. The incision was done 
on the left medial lateral line using the silhouette of the spleen as 
a reference, visible through the skin, and the triangle formed by 
the end of the rib cage and the vertebral column (figure 11). 
Access to the peritoneal cavity allowed the localization of the left 
kidney, caudal and medial from the spleen. Perirrenal fat was 
moved apart and the kidney gently pulled out of the abdominal 
cavity. After that, a knot was tied around the renal hilus and the 
kidney was excised. The peritoneum was sutured with 
Figure 11 Incision site. Left 
kidney is localized slightly 
medial and caudal from the 
spleen. The triangle delimited 
by the end of the rib cage 
and the vertebral column 
defines the area to operate.  
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absorbable thread 5-0 (Vycril) and the skin with non-absorbable thread 5-0 (Ethibond). After 
surgery, a first dose of analgesia with buprenorphine was administered subcutaneous, 
followed by three days of treatment every 12 hours. 
 
Mice were kept in single cages for at least one month after surgery to avoid bites in the 
wound and to facilitate good healing. Since wound healing is impaired in db/db mice (SG 
Keswani 2004, J Michaels 2007), mice were monitored at least twice a day for follow-up and 
wounds were cleaned and disinfected with povidone iodide.  
 
Plasma, urine and tissue collection 
Plasma was collected before starting the treatment, after two weeks and at the end of the 
treatment, before sacrifice. Small blood samples were collected under isoflurane 
anaesthesia in micro centrifuge tubes containing EDTA (5µl of 0.5M solution per 100µl of 
blood) and plasma was separated by centrifugation at 10.000 rpm for 5 minutes and stored 
at -20°C until analysis for creatinine and blood urea nitrogen estimation levels.  
 
Spot urine samples were collected at the same time points as plasma and stored at -20°C 
for albuminuria analysis.  
 
Kidney tissue was collected after cervical dislocation and stored in mRNA later at -20°C for 
mRNA isolation and gene expression analysis. The central part of the kidney was harvested 
for histology.  
 
Glucose measurement 
Glucose was measured every two weeks after 4 hours of fasting with a portable glucometer 
(Accu-Check®). For that purpose, a small incision at the end of the tail was performed to 
obtain approximately 10µl; that amount was enough for the measurement and not harmful 
for the mouse. This was considered the best option for the measurement, since multiple 
factors can influence the labile glucose levels: stress, anaesthesia, time of the day and 
fasting. 
 
Stress causes a prompt raise of catecholamine in the mouse followed by cortisol after few 
hours. These stress hormones increase contraregulatory hormones such as glucagon, 
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which increase glycaemia. For this reason, any manipulation of the mouse in any manner 
can augment glucose values and overestimate them. A rapid cut in the tail with little 
bleeding minimized the stress of the mouse (JE Ayala 2006). A stresless bleeding under 
anaesthesia was for that purpose rejected, since it has been shown that anaesthesia can 
induce hyperglycemia in rodents (ET Brown 2005, Zuurbier CJ 2008). Due to the circadian 
rhythm of cortisol secretion and its influence in glycaemia (Ayala JE1 2010), glucose 
measurement was always performed at the same time, at noon. Additionally, in order to 
minimize interindividual variability ascribed to postpandrial or fasting status, glucose levels 
were measured in all mice after 4 hours of fasting. 
 
Plasma creatinine and plasma BUN 
Plasma creatinine levels were measured using Jaffe’s enzymatic reaction using a 
Creatinine FS kit (DiaSys Diagnostic system, GmBH, Holzheim, Germany). Plasma 
samples were used undiluted and different dilutions of standard were prepared using the 
stock provided with the kit. Working monoreagent was prepared by mixing 4 parts of 
reagent 1 (R1) and 1 part of reagent 2 (R2) provided with the kit. Then, 10 µl of each of the 
diluted samples and standards were added to a 96 well plate with flat bottom (Nunc 
maxisorb plate). The monoreagent (200µl) was added to each well and the reaction mixture 
was incubated for one minute before measuring the absorbance at 492 nm immediately 
after 1 (A1) and 2 (A2) min of addition using an ELISA plate reader. The change in 
absorbance (ΔA) was calculated as: ∆ =  2 − 1
   − 2 − 1
 
 
And creatinine content of samples was calculated as:    = ∆∆        
 
 
Plasma BUN levels were measured using an enzymatic reaction using a Urea FS kit 
(DiaSys Diagnotic System, GmBH, Holzheim, Germany). Different solutions of the standard 
were prepared using the stock provided with the kit. Working monoreagent was prepared by 
mixing 4 parts of reagent 1 (R1) and 1 part of reagent 2 (R2) provided with the kit. Then, 2µl 
of each of the sample and standards were added to a 96 well plate with flat bottom (Nunc 
maxisorb plate). The monoreagent (200 µl) was added to each well and the reaction mixture 
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was incubated for one minute before measuring the absorbance at 360 nm immediately 
after 1 (A1) and 2 (A2) min of addition using an ELISA plate reader. The change in 
absorbance (ΔA) was calculated as: ∆ =  2 − 1
   − 2 − 1
 
 
And BUN content of samples was calculated as: !"   = ∆∆          0,467 
 
 
Urine albumin/creatinine ratio 
Urin albumin levels were determined using an albumin ELISA kit from Bethyl laboratories 
following manufacturer’s instructions. In general the albumin levels in urine samples from 
diabetic mice were quite high, so urine samples were diluted 100 to 1500 times with water 
before estimation. Briefly, a polyethylene flat bottom 96 well plates (Nunc plates) was 
coated with the capture antibody (Anti-Mouse albumin, 1:100 dilution) using 0.05M 
carbonate-bicarbonate (pH 9.6) coating buffer at 4ºC overnight. After incubation, the plate 
was washed 3 times with wash buffer (50 mM Tris, 0,14 M NaCl with 0.05% Tween 20, pH 
8.0) and blocked with blocking solution (50 mM Tris, 0,14 M NaCl with 1% BSA, pH 8.0) at 
room temperature for 1 hour. Following blocking, the plate was washed 5 times with wash 
buffer and the diluted samples/standards added into the respective wells and incubated for 
1 hour. After incubation, the plate was washed 5 times with wash buffer and HRP-
conjugated detection antibody (dilution 1:100.000) was added and incubated in the dark for 
1 hour. Prior to the addition of the TMB reagent (freshly prepared by mixing equal volumes 
of two substrate reagents) the plate was washed 5 times and then incubated in the dark 
until the colour reaction was completed followed by addition of the stop solution (2 M 
H2SO4). The absorbance was read at 450 nm within 10 minutes after the addition of the 
stop solution. The albumin content in each sample was determined using the equation of 
regression line generated by plotting the absorbance of different standards against their 
known concentrations.  
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Urinary creatinine levels were determined, like the plasma creatinine levels using the Jaffe’s 
enzymatic reaction and diluting the samples 10 times (see above Plasma creatinine and 
plasma BUN).  
 
Urinary albumin to creatinine ratio was calculated after converting the values for albumin 
and creatinine to the same unit (mg/dl). Albumin content for each sample (mg/dl) was 
divided by the creatinine content (mg/dl) for the same sample.  
 
Plasma cholesterol and triacylglycerides 
Plasma cholesterol levels were measured using an enzymatic photometric test with a 
Cholesterol FS kit from Diasys following manufacterer’s instructions. Briefly, plasma 
samples were used undiluted and different dilutions of the standard were prepared using 
the stock provided with the kit. Then, 2µl of each sample and standard were added to a 96 
well flat bottom plate (Nunc maxisorb plate). The working reagent (200µl) provided with the 
kit was added to each well and the reaction mixture was incubated in the dark for 20 
minutes at room temperature and subsequently absorbance was measured at 500 nm with 
the ELISA reader.  
 
The amount of cholesterol was calculated as: ℎ   =   ) −  *  −  *     
 
Plasma trigyceride levels were tested with a colorimetric enzymatic assay from Dyasis 
following manufactere’s instructions, being the procedure identical to the one described 
above, with less time of incubation (10minutes).  
 
Plasma triglyceride concentration was then calculated as: +,,   =   ) −  *  −  *     
 
Posteriorly, to correct values for free glycerol, 10mg/dl was substracted from the 
concentration calculated with the formula above. 
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Periodic acid Schiff staining 
Formalin-fixed tissue was processed using tissue processors (Leica). For that paraffin 
blocks were prepared and 2 µm thick paraffin-embedded sections were cut. De-
paraffinization was carried out using xylene (3 times for 5 minutes) followed by re-hydration 
incubating the sections in 100% absolute ethanol (3 times for 3 minutes), 95% ethanol (2 
times for 3 minutes), 70% ethanol (once for 3 minutes) and a final wash with distilled water 
during 5 minutes. Re-hydrated sections were incubated with Periodic acid (2% in distilled 
water) for 5 minutes followed by washing with distilled water for 5 minutes. Then sections 
were incubated with Schiff solution for 2 minutes at room temperature, washed with tap 
water for 7 minutes and counter stained with Hematoxylin solution for 2 minutes. Finally, 
sections were dipped in alcohol 90%, dried and closed with cover slips.  
 
Immunostaining and confocal Imaging 
For immunohistological studies the middle part of the kidney was fixed in 4% formalin 
overnight, processed using tissue processors (Leica) and prepared in paraffin blocks. 2 µm 
thick paraffin-embedded sections were cut. Deparaffinization was done using xylene (3 
times or 5 minutes) followed by re-hydration, which was carried out by incubating the 
sections in 100% absolute ethanol (3 times for 3 minutes), 95% ethanol (2 times for 3 
minutes) and 70% ethanol (once for 3 minutes) followed by washing with PBS (2 times for 5 
minutes). Blocking endogenous peroxidase was carried out by incubating sections in H2O2 
and methanol mixture (20ml of 30% H2O2 in 180 ml of methanol) for 20 minutes in dark 
followed by washing in PBS (twice for 5minutes). Sections were then dipped in antigen 
unmasking solution (3ml of antigen unmasking solution + 300ml of distilled water) and 
cooked in the microwave for a total of 10 minutes (4 times for 2.5 minutes; every 2-5 
minutes water level was checked and made up if necessary  to the initial level with distilled 
water). After microwave cooking sections were cooled to room temperature for 20 minutes 
and washed with PBS. Blocking endogenous biotin was carried out by incubating sections 
with one drop of Avidin (Vector) for 15 minutes followed by incubation with Biotin (Vector) 
for further 15 minutes. After the incubation, sections were washed with PBS (twice for 5 
minutes). 
 
Sections were incubated with different primary antibodies either for 1 hour at room 
temperature or overnight at 4ºC in a wet chamber followed by a wash step with PBS (twice 
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for 5 minutes). After washing sections were incubated with biotinylated secondary 
antibodies (1:300, dilution in PBS) for 30 minutes followed by wash with PBS for 5 minutes 
and Tris for another 5 minutes. Subsequently sections were stained with DAB and 
counterstained with methyl green (Fluka). Later sections were washed with 96% alcohol to 
remove excess of antibody and xylene.  
 
The primary antibodies used in this study are mentioned above. For each immunostaining a 
negative control was used consisting of an isotype control antibody. For confocal imaging, 
sections were labeled with the following primary antibodies: pig anti-mouse nephrin (1:100, 
Acris Antibodies, Herford, Germany) and rabbit anti-mouse WT1 (1:25, Santa Cruz 
Biotechnology, Santa Cruz, CA) and incubated 1 hour in 0.1% milk solution in room 
temperature. After washing, the sections were incubated with the following secondary 
antibodies: guinea pig Alexa Fluor 488 (1:100, Invitrogen, Carlsbad, CA) or rabbit Cy3 
(1:200, Jackson ImmunoResearch Laboratories, West Grove, PA) for 30 minutes at room 
temperature. Stainings were evaluated using confocal microscopy with a LSM 510 
microscope and LSM software (Carl Zeiss AG). 
 
 
Histopathological evaluations 
PAS staining 
Diabetic nephropathy was evaluated by assessing the severity of glomerular damage. The 
following criterion in table 6 was used. For each section 20 glomeruli were evaluated and 
the score was expressed as mean±SEM. 
 
Table 6. PAS glomerular score criterion.  
Score Description 
0 Normal glomerulus 
1 Mild mesangial matrix expansion 
2 Mesangial matrix expansion 
3 Severe mesangial matrix expansion, some closed capillars and/or areas of 
sclerosis 
4 Severe mesangial matrix expansion, capillars completely closed and/or severe 
sclerosis. 
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Mac2 staining 
The number of infiltrated macrophages were counted manually in 20 glomeruli per section 
stained with Mac2 (pan marker for macrophage) antibody. Values are expressed as mean ± 
SEM for each group.  
 
Collagen and p53 staining 
In order to evaluate tissue fibrosis, collagen staining was employed. The software Image J 
was used to quantify the percentage of collagen positive area from each section. The data 
are presented as mean ± SEM per group. This quantification method was also used to 
evaluate the expression of p53 in the kidney. 
 
Wt1/Nephrin staining 
The number of podocytes per glomerulus was quantified by Wt1/Nephrin staining. For each 
section 20 glomeruli were evaluated. Only a clear Wt1 staining surrounded by nephrin 
staining was quantified as a podocyte. Two nuclei that appeared too close together were 
counted as one, as they could belong to the same cell.  
 
 
RNA isolation, cDNA preparation and real-time PCR 
One part of the kidney from each mouse was preserved in RNA-later immediately after 
kidney harvest and stored at -20ºC until processed for RNA isolation. RNA isolation was 
carried out using the RNA isolation kit from Ambion (Ambion, CA, USA). Briefly, tissues 
(~30mg) preserved in RNA-later were homogenized using a blade homogenizer for 30 
seconds in lysis buffer (600 µl) containing 1% β-mercaptothanol. The homogenate was 
centrifuged at 600 rpm for 5 minutes and 350 µl of 70% ethanol was added and mixed 
gently. This whole mixture was then loaded on a RNA column and processed for RNA 
isolation as per manufacturer’s instruction. 
 
The isolated RNA samples were quantified using a Nano drop (PEQLAB Biotechnology 
GmbH, Erlangen, Germany). The ratio of optical densities at 260 nm and 280 nm was an 
indicator for RNA purity (indicative of protein contamination in the RNA samples). Only 
samples with a ratio of 1.8 or more were considered to be of acceptable quality.  
 
Material and methods  
39  
 
 
The isolated RNA samples were quantified and processed for cDNA using reverse 
transcriptase II (Invitrogen, Karlsruhe, Germany). RNA samples were diluted with water to 
get a final concentration of 2µg/20µl, to this diluted RNA samples 13.9 µl of master mix was 
added. The master mix was prepared by mixing 9µl of 5x buffer (Invitrogen, Karlsruhe, 
Germany), 1µl of 25 mM dNTP mixture (Amersham Pharmacia Biotech, Freiburg, 
Germany), 2 µl of 0,1M DTT (Invitrogen, Karlsruhe Germany), 1µl of 40U/µl RNAsin 
(romega, Mannheim, Germany), 0,5µl of Hexanucleotide (Roche, Mannheim, Germany) and 
1µl of Superscript (Invitrogen, Karlsruhe, Germany). The tubes were incubated at 42ºC for 1 
hour and 30 minutes on a thermal shaker followed by 5 minutes heating at 90ºC. Upon 
completion of incubation cDNA samples were stored at -20ºC until used for RT-PCR 
analysis using SYBR green. The cDNA samples prepared as described above were diluted 
1:10 and 2 µl of diluted cDNA samples were mixed with SYBR green master mix (10µl), 
forward primer specific for gene of interest (0,6 µl), reverse primer specific for gene of 
interest  (0,6 µl), Taq polymerase (0,16µl) and distilled water (6,64µl).  
 
The RT-PCR was performed using a Light Cycler 480. Pre-incubation was carried out for 5 
minutes at 95ºC so as to activate the polymerase and complete de-naturation of cDNA 
samples. Then the cDNA was amplified for 40 cycles, each comprising of 15 seconds 
incubation at 95ºC and 45 seconds incubation at 60ºC. For melting curve initially 95ºC for 5 
seconds followed by 65ºC for 1 minute with continuous heating was used. The RT-PCR for 
the reference genes (18s rRNA) was carried out under same conditions. The CT1 (cycle 
threshold) values were calculated using the Light Cycler 480 and the results were 
normalized with respective reference gene expression for each sample. In all cases controls 
consisting of ddH2O were negative for target or reference genes. All designed SYBR green 
primers for all genes evaluated were obtained from Metabion (Metabion, Martinsried, 
Germany).  The oligonucleotide primers in table 7 were used in this study. 
 
 
                                                            1 The cycle threshold (CT) is the number of cycles required for the fluorescent signal to cross the threshold (i.e. exceeds background level).  
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Table 7. Primer sequences used in this study. 
Gene Sequence  
18s Forward 
Reverse 
GCAATTATTCCCCATGAACG 
AGGGCCTCACTAAACCATCC 
Mdm2 Forward 
Reverse 
TGTGAAGGAGCACAGGAAAA 
TCCTTCAGATCACTCCCACC 
P53 Forward TCCGACTGTGACTCCTCCAT 
CTAGCATTCAGGCCCTCATC Reverse 
Bcl-2 Forward 
Reverse 
GGTCTTCAGAGACAGCCAGG 
GATCCAGGATAACGGAGGCT 
Bax Forward 
Reverse 
GATCAGCTCGGGCACTTTAG 
TTGCTGATGGCAACTTCAAC 
PUMA Forward 
Reverse 
CACCTAGTTGGGCTCCATTT 
ACCTCAACGCGCAGTACG 
P21 Forward 
Reverse 
CGGTGTCAGAGTCTAGGGGA 
ATCACCAGGATTGGACATGG 
Nephrin Forward 
Reverse 
TTAGCAGACACGGACACAGG 
CTCTTTCTACCGCCTCAACG 
Wt1 Forward 
Reverse 
GGTTTTCTCGCTCAGACCAGCT 
ATGAGTCCTGGTGTGGGTCTTC 
Synaptopodin Forward 
Reverse 
TCCTTCTCCACCCGGAATGCTG 
AGCCGTCCAGGCTGCTAGGAG 
Podocin Forward 
Reverse 
TGACGTTCCCTTTTTCCATC 
CAGGAAGCAGATGTCCCAGT 
Podocalyxin Forward 
Reverse 
ATAACCAGGCGGTGGCAGTGAA 
CCAGCTTCATGTCACTGACTCC 
CD2AP Forward 
Reverse 
TCCAAAGCCTGACCTGTCAGCT 
CTTTTTGGGCGGGACTTGAGGA 
P50 (NFκB1) Forward 
Reverse 
GCTGCCAAAGAAGGACACGACA 
GGCAGGCTATTGCTCATCACAG 
P65 (RELA) Forward 
Reverse 
TCCTGTTCGAGTCTCCATGCAG 
GGTCTCATAGGTCCTTTTGCGC 
CCL5 Forward 
Reverse 
CCTGCTGCTTTGCCTACCTCTC 
ACACACTTGGCGGTTCCTTCGA 
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CCL2 Forward 
Reverse 
CCTGCTGTTCACAGTTGCC 
ATTGGGATCATCTTGCTGGT 
IL-1β Forward 
Reverse 
ACACACTTGGCGGTTCCTTCGA 
GTTCATCTCGGAGCCTGTAGTG 
TNFα Forward 
Reverse 
CCACCACGCTCTTCTGTCTAC 
AGGGTCTGGGCCATAGAACT 
iNOS Forward 
Reverse 
TTCTGTGCTGTCCCAGTGAG 
TGAAGAAAACCCCTTGTGCT 
IL-12α Forward 
Reverse 
GTTCATCTCGGAGCCTGTAGTG 
CCTCATAGATGCTACCAAGGCAC 
IL6 Forward 
Reverse 
TGATGCACTTGCAGAAAACA 
ACCAGAGGAAATTTTCAATAGGC 
Fibronectin Forward 
Reverse 
CCCTATCTCTGATACCGTTGTCC 
TGCCGCAACTACTGTGATTCGG 
aSMA (ACTA1) Forward 
Reverse 
ACCATCGGCAATGAGCGTTTCC 
GCTGTTGTAGGTGGTCTCATGG 
Col1a1 Forward 
Reverse 
CCTCAGGGTATTGCTGGACAAC 
CAGAAGGACCTTGTTTGCCAGG 
Col4a1 Forward 
Reverse 
ATGGCTTGCCTGGAGAGATAGG 
TGGTTGCCCTTTGAGTCCTGGA 
Laminin Forward 
Reverse 
TGTCTGCAAGCCAGGAGCTACA 
GAGACAGAACGGCATCACCAAC 
TGFβ Forward 
Reverse 
GGTCTGGAGAATCTTCAGGAACC 
CACCACTGGAAGAGGAGAATGG 
Abbreviations: Bcl-2 = B-Cell lymphoma 2, PUMA = p53 upregulator of apoptosis, Wt1 = wilms tumour protein 1, 
CD2AP = CD2 associated protein, TNFα = tumour necrosis factor α, iNOS = inducible nitric oxide synthase, 
aSMA = actin, alpha skeletal muscle, ACTA1 = actin alpha 1, Col1/4 = collagen type 1/4, TGFβ = transforming 
growth factor beta. 
 
 
3.2.2 In-vitro methods 
Podocyte cell culture 
A conditionally immortalized mouse podocyte cell line was used for the in vitro experiments. 
This cell line is highly proliferative under permissive conditions and undergoes growth arrest 
within 6 days when those conditions are removed. During growth arrest, the cells 
differentiate into mature podocytes, in a similar way as podocytes in vivo (P Mundel 1997). 
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Both non differentiated and differentiated podocytes express Wt1, and as the cytoskeleton 
is rearranged and foot processes are formed, proteins such as synaptopodin, nephrin and 
podocalyxin, among others, are expressed (SJ Shankland 2007).  
 
Cells were cultured in RPMI 1640 with glutamine (Gibco) medium containing 5% HEPES, 
5% Bicarbonate, 5% Pyruvate, 5% fetal bovine serum and 1% penicillin/streptomycin. Cells 
were expanded under permissive conditions – 33ºC and 50U/ml INFγ- and then seeded in 
96 well flat bottom plates (12.000 cells/well). To allow for a complete differentiation into 
podocytes, cells were kept under nonpermissive conditions for 15 days at 37ºC without 
INFγ and then stimulated.  
 
Mouse tubular cells culture 
Moue tubular cells were cultured in DMEM medium (Biochron) containing 10% fetal bovine 
serum and 1% penicillin/streptomycin and kept at 37ºC.  
 
Cell freezing and thawing 
At earlier passages large amounts of cells were grown first under standard culture 
conditions and then frozen for future cell culture experiments. For freezing, detached cells 
from the culture plates were collected and centrifuged under sterile conditions for 3 minutes 
at 100 rpm. The cell pellet was maintained on ice and carefully re-suspended in cold 
freezing medium (90% respective culture medium and 10% DMSO) by pipetting the 
suspension repeatedly up and down. 1,5 ml aliquots were quickly dispensed into freezing 
vials (4ºC). The cells were slowly frozen at -20°C for 1 hour and then at -80^C overnight. 
The next day, all aliquots were transferred into the liquid nitrogen for long-term storage.  
For thawing frozen cells, a vial was removed from the liquid nitrogen and put in to the water 
bath at 37°C. The cells were then dispensed in 5ml of warm complete growth medium and 
centrifuged at 100 rpm for 5-7 minutes to remove the old media and DMSO. After 
centrifugation, cells were resuspended in fresh medium and transferred into a new culture 
plate. The medium was changed one more time after 24 hours.  
 
In-vitro assessment of cell death 
To analyze cytotoxicity, lactate dehydrogenase (LDH) release was measured via a 
colorimetric assay (Cytotoxicity Detection Kit (LDH), Roche). Podocytes were seeded in a 
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collagen-coated 96 well plate (12.000 cells/well) and differentiated for 15 days under non-
permissive conditions. After 15 days, serum was removed – except for the survival control 
group - and cells were either cultured in normal glucose media (11mM) or high glucose 
media (45mM).  After 24 hours, cells were stimulated with different concentrations of Nutlin-
3a or with vehicle alone, dymethil sulfoxide (DMSO), as a control. Triton X was additionally 
administered as positive control. The same protocol was used for mouse tubular cells, 
although no differentiation of these cells was needed, nor a coated plate. The density of 
cells per well was for MTC 8.000 cells/well. 
 
After 6 and 24 hours, 100 µl of the supernatant was collected and transferred into a NUNC 
96 well plate. 100 µl of freshly prepared reagent, containing 11,25 ml of catalyst and 250 µl 
of dye solution, was added and after 20 minutes the absorbance was measured with an 
ELISA reader at 492 nm. A background control was employed for each group.  
 
The average absorbance values of each group were calculated and then the value of the 
background control was substracted. The percentage of cytotoxicity was then calculated as: ,, %
 = .. .0 − *01.    100 
 
 
In vitro viability assessment 
Cell viability was tested to complement cytotoxicity assessment with an MTT assay. This 
assay measures via absorbance the amount of tetrazolium dye MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium) that has been reduced to its insoluble form formazan by 
NAD(P)H-dependent cellular oxidoreductase enzymes, which reflect the number of 
metabolically active and viable cells. 
 
Cells were seeded as described above (In-vitro assessment of cell death) and after 6 and 
20 hours, the MTT dye solution was added to the cells at a volume of 15 µl. After 4 hours, 
the reaction was stopped with MTT stop solution and the plate left overnight covered in 
aluminum foil. The following day, absorbance was measured with the ELISA reader at 570 
nm.  
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3.2.3 Statistical analysis 
Data are presented as mean ± SEM. For multiple comparison of groups one way ANOVA 
was used followed by Tukey’s Multiple Comparison Test. Student’s T-test or Mann Whitney 
test (when normality could not be assumed) were used for the comparison of single groups 
and 2-Way-ANOVA when two groups were compared over different time-points. Statistical 
analysis was conducted with GraphPrism. A value of p<0,05 was considered of statistical 
significance.   
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4. RESULTS 
 
4.1 Mdm2 blockade with Nutlin-3a in mouse podocytes and mouse tubular cells 
To test whether blockade of Mdm2 with Nutlin-3a in podocytes can also increase cell death 
similar to that seen in siRNA studies (Thomasova D 2015), mouse podocytes were cultured 
under normal glucose conditions and stimulated after complete differentiation (see section 
above 3.2.2 In vitro methods, Podocyte cell culture) with different doses of the drug -10, 15 
and 20µM- and, as a control, with its vehicle (DMSO) in a concentration comparable to the 
group with the highest dose of Nutlin-3a. Using a MTT assay, the viability of cells, in terms 
of their capacity of reducing MTT into formazan –a reaction that is proportional to the 
measured absorbance at 570nm- was assessed (see section above 3.2.2 In vitro methods, 
In vitro viability assessment). As shown in figure 12A, treatment of podocytes with Nutlin-3a 
decreased the absorbance in a dose-dependent manner after 12 hours, although not 
significantly. However, after 24 hours (figure 12B) the decreased absorbance, illustrating 
reduced viability, becomes significant in comparison to the not stimulated group (NG) and to 
the vehicle group (NG+DMSO). To confirm this data, we further performed an LDH assay to 
determine the cytotoxic effect of Nutlin-3a on podocytes. After 6 and 24 hours, the 
cytotoxicity significantly increased when cells were treated with a higher dosage of Nutlin-3a 
compared to control groups (figure 12C and 12D).  
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Figure 12. Viability (MTT assay) and cytotoxicity (LDH assay) in mouse podocytes. A) Stimulation with 
Nutlin-3a significantly reduced podocyte viability after 12 hours of stimulation compared to control. The 
difference with the vehicle however showed no significance. B) After 24 hours, this difference between Nutlin3a 
and vehicle becomes statistically significant (p<0,0005). C-D) Cytotoxicity also increased significantly with 
Nutlin-3a compared to control and vehicle in a dose-dependent manner. Triton X was used as negative control 
in the viability assay and as positive control and reference for the cytotoxicity assay. On the other hand, 
podocytes cultured in media with 5% serum represented the survival control. n=5 for each group. Data was 
analysed using 1-way ANOVA with Tukey’s Multiple Comparison Test. NG = normal glucose media (11mM); 
NG+10 = normal glucose media with 10µM of Nutlin-3a; NG+15 = normal glucose media with 15µM of Nutlin-3a; 
NG+20 = normal glucose media with 20µM of Nutlin-3a; NG+DMSO = normal glucose with 20µl/ml of DMSO. * = 
p<0,05; ** = p<0,005; *** = p<0,0005. 
 
Next, we wanted to investigate the effect of Nutlin-3a on the viability (MTT assay) and 
cytotoxicity (LDH assay) of mouse tubular cells (MTCs) under normal glucose conditions. 
As represented in figure 13A and 13B, treatment of MTCs with Nutlin-3a resulted in a 
decreased absorbance in the MTT assay after 12 and 24 hours in a dose-dependent 
manner, indicating that Nutlin-3a reduces the viability of MTCs. Next, an LDH assay was 
performed to determine the cytotoxic effect of Nutlin-3a. Like in podocytes, Nutlin3a was 
also cytotoxic to MTCs as indicated by a significant increase in the percentage of 
cytotoxicity after 6 and 24 hours (figure 13C and 13D, respectively).  
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Figure 13. A-B) Viability (MTT assay) and C-D) cytotoxicity (LDH assay) in mouse tubular cells. A) 
Stimulation with Nutlin-3a reduced tubular cell viability after 12 hours and B) after 24 hours post-stimulation 
compared to control and vehicle, being statistically significant at the later time point. C-D) Nutlin-3a stimulation 
increased significantly cytotoxicity in a dose-dependent manner after 6 and 24 hours. Triton X was used as 
negative control for the MTT assay and as positive control and reference for the cytotoxicity assay. Podocytes 
cultured in media with 5% serum served as survival control. n = 5 for each group. NG = normal glucose media 
(5,5mM); NG+10 = normal glucose media with 10µM of Nutlin-3a; NG+15 = normal glucose media with 15µM of 
Nutlin-3a; NG+20 = normal glucose media with 20µM of Nutlin-3a; NG+DMSO = normal glucose with 20µl/ml of 
DMSO. Data was analyzed using 1-way ANOVA with Tukey’s Multiple Comparison Test. * = p<0,05; ** = 
p<0,005; *** = p<0,0005. 
 
To look whether a diabetic environment had an impact on the viability and cytotoxicity of 
podocytes and MTCs, stimulation with high glucose was carried out. Podocytes were 
cultured in high glucose serum-free media (25mM) for 24 hours and then MTT and LDH 
assays were performed 30/36 hours and 48 hours later. As shown in figure 14A, the viability 
of podocytes exposed to high glucose media was significantly higher than those to normal 
glucose media (11mM). Accordingly, cytotoxicity was significantly lower under diabetic 
conditions than normal glucose conditions after 24 hours. The culture of MTCs with high 
glucose media did not cause any difference in terms of viability compared  to normal 
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glucose media (figure 14B) but the cytotoxicity after 48 hours was significantly higher in 
normal glucose than in high glucose conditions (p<0,0005), similar to that seen in 
podocytes. 
 
To further investigate the effect of Nutlin-3a in diabetic conditions, the same viability and 
cytotoxicity assays were performed in podocytes cultured in a high glucose environment 
(45mM). Again, stimulation of podocytes stimulated with Nutlin-3a present a decreased 
viability after 12 hours (figure 15A) with a significant reduction of cell viability observed after 
24 hours compared to vehicle (figure 15B). Cytotoxicity assessed using an LDH assay 
showed that stimulation with Nutlin-3a caused a significant increase in podocyte cytotoxicity 
compared to control and vehicle in a dose-dependent manner after 6 and 24 hours (figure 
15C and 15D), as observed under normal glucose conditions.  
 
 
Figure 14. Viability (MTT assay) and cytotoxicity (LDH assay) in mouse podocytes and mouse tubular 
cells exposed to normal (5,5-11mM) or high glucose media (45mM). A) An environment rich in glucose 
increases mouse podocyte viability and reduces significantly cell death after 48 hours. B) Mouse tubular cells 
presented by contrast no statistical difference in viability but again they did in cytotoxicity in the later time point, 
being significantly greater in a normal glucose than in high glucose media. Data was analyzed with t-test.n = 10 
in each group. NG = normal glucose media (5-10mM); HG = high glucose media (25mM). * = p<0,05; ** = 
p<0,005; *** = p<0,0005. 
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Figure 15. Viability (MTT assay) and cytotoxicity (LDH assay) in mouse podocytes cultured in high 
glucose media (45mM). A) Podocyte stimulation with Nutlin-3a in a high glucose media reduces significantly 
cell viability in a dose-dependent manner compared to control after 12 hours and B) after 24 hours, which was 
significantly different compared to vehicle. C-D) Nutlin-3a stimulation in podocytes exposed to high glucose 
media increases significantly the cytotoxicity  in a dose-dependent manner compared to control and vehicle after 
6 and 24 hours. Triton X was used as negative control in the viability assay and as positive control and reference 
for the cytotoxicity assay. Manitol (25mM) was used as control of osmolarity for the high glucose environment. 
No statistical differences were found between manitol and high glucose that could suggest a negative effect of 
high glucose media in cell osmolarity. Data was analyzed with 1 way ANOVA withTukey’s Multiple Comparison 
Test. n = 5 per group. HG = high glucose media; HG+10 = high glucose media with 10µM of Nutlin-3a; HG+15 = 
high glucose media with 15µM of Nutlin-3a; HG+20 = high glucose media with 20µM of Nutlin-3a; HG+DMSO = 
high glucose with 20µl/ml of DMSO. * = p<0,05; ** = p<0,005; *** = p<0,0005. 
 
In the same way, the effect of Nutlin-3a on MTCs exposed to high glucose levels was 
determined regarding viability and cytotoxicity. The viability after 12 and 24 hours of 
stimulation with Nutlin-3a significantly decreased compared to control, but not to vehicle 
(figure 16A and 16B). The percentage of cytotoxicity was not significantly higher following 
Nutlin-3a treatment compared to vehicle after 6 hours (figure 16C) and 24 hours (figure 
16D).  
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Figure 16. Viability (MTT assay) and cytotoxicity (LDH assay) in mouse tubular cells cultured in high 
glucose media (45mM). A) Stimulation of mouse tubular cells with Nutlin-3a of exposed to high glucose media 
reduced significantly the cell viability in a dose-dependent manner compared to control after 12 hours. B) After 
24 hours, viability was also significantly reduced after Nutlin-3a stimulation compared to control but not to 
vehicle. C) Cytotoxicity in MTCs exposed to high glucose media increased in the Nutlin-3a-treated groups 
compared to control after 6 hours, but the difference was not significant compared to vehicle. D) After 24 hours 
of stimulation with Nutlin-3a no significant differences were seen among the groups. Triton X was used as 
negative control in the viability assay, and as positive control and reference for the cytotoxicity assay. Manitol 
(25mM) was used as control of osmolarity for the high glucose environment. No statistical differences were 
found between manitol and high glucose that could suggest a negative effect of high glucose meda in cell 
osmolarity. Data was analyzed with 1-way ANOVA with Tukey’s Multiple Comparison Test. n = 5 per group. HG 
= high glucose media; HG+10 = high glucose media with 10µM of Nutlin-3a; HG+15 = high glucose media with 
15µM of Nutlin-3a; HG+20 = high glucose media with 20µM of Nutlin-3a; HG+DMSO = high glucose with 20µl/ml 
of DMSO. * = p<0,05; ** = p<0,005; *** = p<0,0005.  
 
Taken together, Mdm2 blockade with Nutlin-3a increased the cytotoxicity and decreased the 
viability of mouse podocytes and tubular cells under normal glucose condition (11 and 
5,5mM, respectively). In mouse podocytes under high glucose concentration the cytotoxicity 
also increased and the viability decreased following Nutlin-3a treatment. In mouse tubular 
cells in a hyperglycaemic milieu however a significant difference compared to vehicle was 
not observed. 
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4.2 Pharmacological blockade of Mdm2 with Nutlin-3a in healthy mice 
After Nutlin-3a showed to induce cell death in mouse podocytes and tubular cells in vitro, 
we further wanted to test whether Nutlin-3a could have deleterious effects in vivo. 
Therefore, wild type C57B/6J mice were randomly divided into three groups: one group was 
injected with 20 mg/kg Nutlin-3a for four weeks every two days, the second group was 
injected with vehicle for four weeks every two days, and a third group received no 
intervention and served as a control to exclude any effects of the vehicle treatment.  
 
4.2.1 Nutlin-3a-treated mice present higher mortality and lower body weight 
During the treatment, three mice died in the Nutlin-3a-treated group (72% survival), while all 
vehicle and control mice reached the end point of the study (figure 17C). Although a 
necropsy was performed on these mice, no macroscopic cause of death was found. A 
systemic toxic effect of the drug or a renal failure could hence not be excluded. Along the 
treatment, the body weight and blood glucose levels were monitored. After the first week of 
treatment, the body weight of Nutlin-3a-treated mice decreased, whereas in the vehicle and 
control mice the body weight continued to increase progressively (figure 17A). At the end of 
the study, the body weight of Nutlin-3a-treated mice (24,62 ± 0,36 g) was significantly lower 
compared to both the vehicle (28,78 ± 0,84 g; p<0,0005) and the control (27,23 ± 0,66 g; 
p<0,05) group (figure 17B).  
 
As the effect of Nutlin-3a in the kidney might resemble some molecular features of diabetic 
nephropathy, glycaemia was also monitored during the treatment to exclude that high blood 
glucose levels could be the reason for such similarity in the kidney outcome. At the end of 
the study, we observed a significant difference in glycaemia as demonstrated by a 
significant decrease of plasma glucose levels in Nutlin-3a-treated mice (141,8 ± 7,3 mg/ml) 
compared to vehicle-treated mice (170,7 ± 7,5 mg/ml; p<0,05), indicating that Nutlin-3a had 
no diabetogenic effect (figure 17D). 
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Albuminuria, measured as albumin/creatinine ratio, was evaluated in spot urine samples 
collected before starting the Nutlin-3a treatment, then two weeks after and at the end of the 
study. As expected, control (0,4 ± 0,16) and vehicle mice (0,3 ± 0,04) displayed a normal 
range of albumin creatinine ratio, indicating a competent glomerular filtration barrier. 
However, following Nutlin-3a treatment, albuminuria significantly increased compared to 
control and vehicle mice three weeks after the start of the treatment (1,66 ± 0,3) and at the 
end of the study (2,0 ± 0,6; p<0.05) (figure 18C and D). 
 
 
Figure 18 Renal functional parameters. A) Plasma creatinine levels increased in the Nutlin-3a group (2.8 ± 
1.4 mg/dl) compared to vehicle and control (1.8 ± 0.7 and 1.7 ± 0.6 mg/dl, respectively), but not significantly. B) 
Blood urea nitrogen (BUN) levels at the end of the study significantly increased in Nutlin-3a-treated group (36.2 
± 3.6 mg/dl) compared to vehicle (23.9 ± 3.2 mg/dl) (p<0,05), but not to control (26.7 ± 1.7 mg/dl). C-D) 
Albumin/creatinine ratio increased slightly after the first week of treatment and strikingly at the end of the 
treatment, being significantly higher compared to vehicle and control (p<0.05). Data were analysed with 1-way 
ANOVA with Tukey’s Multiple Comparison Test. n(Control) = 3; n(Vehicle) = 6; n(Nutlin-3a) = 5. ns = statistically 
not significant; * = p<0,05. 
 
Results  
54 
 
 
 
 
Figure 19 Glomerular PAS score and mRNA expression. A) Representative pictures of each group. Original 
magnification 40x. (Arrow: mild mesangial expansion). B) Semiquantification of glomerular damage in PAS 
stained slides of paraffin-fixed kidney tissue. While control and vehicle mice have an average of 0.11±0.05 and 
0.20±0.13, being 0 considered as normal and 1 as mild mesangial proliferation, Nutlin-3a-treated mice present a 
significant higher score with an average of 0.50±0.14. C) Gene expression of tubular injury markers appear 
upregulated in Nutlin-3a mice. Data was analysed with 1 way ANOVA with Tukey’s Multiple Comparison Test. 
n(Control) = 3; n(Vehicle) = 6; n(Nutlin-3a) = 5. ns = statistically not significant; * = p<0,05. 
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The functional parameters have shown a significant increase in proteinuria associated with 
higher BUN levels in the Nutlin-3a-treated group. To analyse the glomerular morphology of 
the kidneys, kidneys were harvested at the end of the study and embedded in paraffin, and 
kidney sections stained for Periodic Acid Schiff (PAS). As illustrated in figure 19A and B, 
glomerular morphology was evaluated using a glomerular score (GS) in a blind manner with 
the following criteria: 0 for normal glomerulus, 1 for mild mesangial matrix expansion, 2 for 
moderate to severe mesangial matrix expansion with no sclerotic segments, 3 for severe 
mesangial matrix expansion, partially closed capillaries and sclerotic segments and 4 for 
collapsed glomerulus and total sclerosis. A minimum of 20 glomeruli were scored for each 
mouse. The histopathology of all mice was normal, except for a mild mesangial matrix 
expansion in the Nutlin-3a-treated group (GS Nutlin-3a group 0.50 ± 0.14 versus GS control 
0.11 ± 0.05 and GS vehicle 0.20 ± 0.13) compared to vehicle and control (p<0.005) (figure 
19A). Although no tubular damage was observed via histopathology, total mRNA levels of 
neutrophil gelatinase-associated lipocalin (NGAL)1 (p=0,07) and kidney injury molecule-1 
(Kim-1)2 (p<0,05) were upregulated in kidneys of Nutlin-3a-treated mice compared to the 
control and vehicle group, indicating an incipient tubular damage (figure 19C). 
 
 
4.2.3 Nutlin-3a promotes Mdm2 and p53 gene expression and increases p53 protein 
levels 
By binding to the N-terminal p53 binding domain, Nutlin-3a blocks the interaction between 
Mdm2 and p53. The direct consequence of this blockade is the elevation of p53 levels 
(Shangary S. 2009, Nicholson 2014), since p53 is stabilized and cannot longer be degraded 
in the proteasome system. As illustrated in figure 20A and B, a higher expression of p53 in 
Nutlin-3a-treated mice was observed compared to the vehicle and control group by 
immunohistochemistry (figure 22A). Further quantification of the percentage of the stained 
area showed significantly higher p53 levels (% of black area) in the Nutlin-3a-treated group 
compared to the vehicle and control group (figure 20B). Additionally, mRNA levels of Mdm2 
and p53 in the kidney of Nutlin3a-treated mice were significantly elevated compared to the 
vehicle and control group (figure 20C).                                                             1 Neutrophil gelatinase-associated lipocalin (NGAL) is produced in the distal nephron and its synthesis is up-
regulated in response to kidney injury {Devarajan P, 2008 #182}. 2 Kidney injury molecule-1 (Kim1) is a type 1 transmembrane protein, whose expression is markedly up-
regulated in the proximal tubule in the post-ischemic rat kidney (Han WK, 2002).  
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vehicle. However, no difference was observed in the gene expression levels of PUMA 
between all groups.  
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Figure 21. Gene expression of p53-related target genes. The pro-apoptotic genes Bcl-2 and Bax are 
upregulated in the Nutlin-3a group compared to vehicle and control (p<0,05), whereas mRNA levels of PUMA 
did not differ between groups. The gene expression of cyclin-dependent kinase inhibitor p21 is also upregulated 
in the Nutlin-3a-treated group compared to vehicle (p<0,05), but not to control. Data was analysed with 1-way 
ANOVA with Tukey’s Multiple Comparison Test. ns = statistically not significant; * = p<0,05; ** = p<0,005. 
 
 
4.2.4 Nutlin-3a-treated mice display less number of podocytes  
In order to investigate the effect of Nutlin-3a on podocytes, kidneys were stained with the 
classical podocyte markers Wilms tumor protein 1 (Wt-1) and Nephrin. As illustrated in 
Figure 22A, Wt1, a transcription tumor protein important for the development of the 
urogenital system that locates in the nuclei of renal cells was marked in red and Nephrin, a 
structural component of the slit diaphragm, in green. The number of podocytes was counted 
in at least twenty different glomeruli for each kidney. As seen in figure 22B, while control 
and vehicle group showed a count of 15,87 ± 0,35 and 13,66 ± 0,68, respectively, Nutlin-3a 
had a significantly lower number of podocytes (11,55 ± 0,48; p<0,05).  
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4.2.5 Nutlin-3a promotes inflammation in healthy mice 
It has been shown, that inhibition of Mdm2 with Nutlin-3a can also attenuate inflammation 
through inhibition of the NFκB pathway (Mulay SR 2012, Thomasova D. 2012). Therefore, 
we analysed the gene expression of the NFκB subunits p50 and p65 to investigate the 
inhibitory effect of Nutlin-3a. Surprisingly, mRNA levels of both subunits of the nuclear factor 
NFκB were upregulated (p<0.05), as shown in figure 23A. To further look into how 
inflammation was affected by Nutlin-3a administration, intrarenal mRNA levels of tumor 
necrosis factor α (TNFα), inducible nitric oxide synthase (iNOS), monocyte chemotactic 
protein 1 (MCP1 or CCL2), CCL5, interleukin 6 (IL-6), interleukin 12a (IL-12a) and 
interleukin 1β (IL-1β) were analysed by RT-PCR. As represented in figure 23B, treatment 
Figure 22. Wt-1/Nephrin staining and podocyte 
count. A) Representative pictures of each group. 
In red, Wt1; in green, Nephrin. B) Quantification. 
The number of podocytes in the Nutin-3a-treated 
group was significantly lower (11,55 ± 0,48) than 
the one in the vehicle group (13,66 ± 0,68) and 
control group (15,87 ± 0,35). Data was analysed 
with the average of podocytes per glomerulus in 
each kidney, involving a minimum of 20 glomeruli 
for each kidney. 1-way ANOVA with Tukey’s 
Multiple Comparison Test was applied. ns = 
statistically not significant; * = p<0,05; ** = 
p<0,005.  
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with Nutlin-3a upregulated significantly the mRNA levels for all inflammatory markers 
compared to vehicle and control.   
 
 
 
Figure 23 Gene expression of NFκB and inflammatory markers. A) mRNA levels of the NFκB subunits, p50 
and p65, appear significantly upregulated in the Nutlin-3a-treated group compared to control and vehicle 
(p<0,05). B) mRNA levels of CCL5, CCL2, IL-1β, TNFα, iNOS, IL-12a and IL-6 are significantly upregulated in 
Nutlin-3a-treated mice compared to vehicle (p<0.05). Data was analysed with 1-way ANOVA with Tukey’s 
Multiple Comparison Test. ns = statistically not significant; * = p<0,05; ** = p<0,005. 
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One hallmark of an inflammatory response is the infiltration of macrophages. To investigate 
whether the previously observed inflammatory response of Nutlin-3a was also inducing the 
infiltration of macrophages, kidney sections were stained with the Mac2 antibody and the 
number of macrophages in each glomerulus counted. Consistent with the upregulation of 
inflammatory markers following Nutin-3a treatment, the number of infiltrating macrophages 
into the glomerulus was significantly higher in this group compared to vehicle as illustrated 
by immunohistochemistry in figure 24A. The average number of macrophages counted in 
the glomeruli was 0,59 ± 0,11, whereas in the Nutlin-3a-treated group an average of 0,98 ± 
0,11 was observed (figure 24B). 
 
 
 
 
 
 
 
Figure 24. Glomerular macrophage infiltration. 
A) Representative pictures of Mac2 staining of 
kidney sections from vehicle and Nutlin-3a-treated 
mice. Arrows point at stained macrophages. B) 
Quantification. The average number of 
macrophages in the Nutlin-3a-treated group (0,98 
± 0,11) is significantly higher than that observed in 
the vehicle group (0,57 ± 0,11) (p<0,05). The 
difference however with the control group (0,61 ± 
0,13) is not statistically significant. On the left a 
picture of a representative glomerulus for the 
vehicle and Nutlin—3a group is displayed. Arrows 
point at stained macrophages. Data was analysed 
with 1-way ANOVA with Tukey’s Multiple 
Comparison Test. ns = statistically not significant; 
* = p<0,05.. 
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Figure 25. Gene expression of fibrosis markers. There are no significant differences between groups in the 
gene expression of fibrotic markers such as Fibronectin, aSMA, Col1a1 and Coll4a1. However, expression of 
Laminin (p<0,05) and TGFβ (p<0,05) are significantly upregulated compared to vehicle and control. Data was 
analysed with 1-way ANOVA with Tukey’s Multiple Comparison Test. ns = statistically not significant; * = p<0,05; 
** = p<0,005 
   
The effect of Nutlin-3a on renal fibrosis was also investigated. As shown in figure 25, 
intrarenal mRNA expression levels of fibronectin, collagen and aSMA did not significantly 
change in Nutlin-3a-treated mice compared to the vehicle and control group. In contrast, the 
mRNA expression of the fibrosis markers laminin (p<0,005) and TGFβ (p<0,005) were 
significantly upregulated in Nutlin-3a-treated mice, indicating that Nutlin-3a induced renal 
fibrosis to some extent.  
 
In addition, to look at fibrosis was further using immunohistochemistry, kidney sections were 
stained with collagen 1 (Col1) and the percentage of the stained area quantified via 
microscopy and the program Image J. As illustrated in figure 26A, kidney sections from 
Nutlin-3a-treated mice showed no difference in the staining quality of Col1 (black colour) 
compared to the vehicle and control group. That was further quantified by determining the 
percentage of the black stained area between the groups (p=0,52) (figure 26B).  
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Figure 26. Collagen 1 immunohistochemistry. 
A) Representative pictures of collagen 1 staining 
for each group. No significant differences were 
observed between groups. Pictures were 
analysed with Image J. B) Quantification of the 
percentage of stained area. Data was analyzed 
using 1 way ANOVA and Tukey’s Multiple 
Comparison Test. ns = statistically not significant.  
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Glycaemia was monitored along the treatment with either Nutlin-3a or placebo in db/db 
mice. Throughout the experiment, there was no difference observed in glycaemia, as 
indicated by the plasma glucose levels after 20 weeks: 669,5 ± 142,2 mg/ml in Nutlin-3a-
treated mice and 765,0 ± 46,8 mg/ml in vehicle (figure 27B). 
 
Additionally, uninephrectomized db/db mice were either fed a control diet, a normal chow 
diet containing 4,5% fat, or a high fat diet containing 10% fat (9% pork lard and 1% 
soyabean oil) to aggravate the complications of diabetic nephropathy and to mimic closer 
the human features of T2D. In order to investigate whether the high fat diet had an influence 
on the blood lipid levels, blood was collected from uninephrectomized db/db mice that were 
fed a high fat or normal chow diet, and triacylglyceridemia and cholesterolemia were 
analysed after 12, 16 and 20 weeks.  
 
As illustrated in figure 28A, blood levels of triacylglycerides did not change in high fat diet 
fed mice compared to a normal diet, except at the beginning, at week 12, when 
paradoxically triacylglyceride levels appeared significantly higher in mice fed with normal 
chow diet than in mice fed with high fat diet (157,4 ± 2,79 vs 201,2 ± 8,09 g/dl at 12 weeks, 
p<0,5; 145,7 ± 18,28 vs 161,9 ± 14,87 mg/dl at 16 weeks, p=0,51; 444,2 ± 42,87 vs 436,7 ± 
55,19 mg/dl at 20 weeks, p=0,92). In contrast, cholesterol levels significantly increased in 
mice fed with a high fat diet compared to mice fed with a normal chow diet (176,5 ± 11,74 
vs 122,7 ± 6,55mg/dl at 12 weeks, p<0,005, 133,4 ± 8,79 vs 86,12 ± 5,67 mg/dl at 16 
weeks, p<0,0005, 192,2  ± 28,09 vs. 106,7 ± 10,48 mg/dl at 20 weeks, p<0,05), as seen in 
figure 28B.  
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Figure 28 Cholesterolemia and triacylgliceridemia. A high fat diet (10% fat content) was employed in the 
study, to emulate closer the human environmental factors of diabetes type II. As a control, blood of diabetic mice 
with the same background and age, which also underwent uninephrectomy, was concurrently analysed with a 
colorimetric assay. A) Triacylgliceride levels increased significantly over time (p<0,0001) but were not affected 
by a diet richer in fat content (p=0,36); however, B) cholesterolemia was significantly higher in these mice than 
in those fed with a normal diet (p<0,0001) . Data were analysed with 2-Way-ANOVA. UNI = uninephrectomized; 
ND = normal diet (4,5% fat content); HFD = high fat diet (10% fat content); ns = statistically not significant; * = 
p<0,05; ** = p<0,005; *** = p<0,0005.  
 
4.3.2 Treatment with Nutlin-3a in diabetic mice aggravates renal function 
To evaluate global renal function, blood urea nitrogen (BUN) levels and plasma creatinine 
levels were measured in plasma samples from uninephrectomized db/db mice that were on 
a high fat diet with or without Nutlin-3a treatment. As shown in figure 29A, plasma creatinine 
levels were higher but not statistically significant in Nutlin-3a-treated db/db mice (2.10 ± 
0.23 mg/dl) compared to the vehicle group (1.33 ± 0.06 mg/dl, p=0,09). Plasma BUN levels 
were determined after 15 weeks prior to Nutlin-3a treatment and after 17 and 20 weeks 
following treatment with Nutlin-3a (figure 29B). Prior to Nutlin-3a treatment, no difference in 
the BUN level was observed between groups, whereas treatment with Nutlin-3a increased 
the BUN levels in Nutlin-3a-treated mice compared to the vehicle group after 20 weeks 
(vehicle group 39,5 ± 7,8 mg/dl vs. Nutlin-3a group 69,1 ± 12,4 mg/dl, p<0,01, n=3). After 17 
weeks, although BUN levels also increased, the difference between two groups was not 
statistically significant (vehicle-group 48,5 ± 2,8 mg/dl vs. Nutlin-3a group 55,5 ± 1,2 mg/dl, 
p>0,05 n=7).  
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To investigate the glomerular function, albuminuria was assessed by measuring the 
albumin/creatinine ratio. This was evaluated in spot urine samples collected prior to the 
treatment with Nutlin-3a, two weeks after and at the end of the study (20 weeks). As 
depicted in figure 29C, albuminuria increased as the disease progressed until week 17 and 
decreased after. This trend could be explained due to the high mortality rate at the end of 
the study, resulting in a survival bias. After 20 weeks, the difference in albuminuria between 
vehicle and Nutlin-3a-treated groups was not statistically significant (albumin/creatinine ratio 
in vehicle 5,6 ± 1,1 vs. albumin/creatinine ratio in Nutlin-3a-treated 7,1 ± 1,2, p=0,3) (figure 
29D).  
 
Figure 29. Renal functional parameters. A) Plasma creatinine levels are increased in Nutlin-3a group (2.10 ± 
0.23 mg/dl) compared to vehicle (1.33 ± 0.06 mg/dl), but not significantly (p=0,09). B) Blood urea nitrogen (BUN) 
levels increased overtime, being significantly higher after four weeks of treatment with Nutlin-3a (p<0,05).. C-D) 
Albuminuria as means of albumin/creatinine ratio appeared not significantly different between groups. Data was 
analysed with Man Whitney Test for A and D, and with 2-Way-ANOVA for B. n(Vehicle) = 4, n(Nutlin-3a) = 6.  ns 
= statistically not significant; * = p<0,05 
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While the renal functional parameters showed a trend towards a worse outcome in the 
Nutlin-3a-treated db/db mice, the renal histological architecture presented only mild 
glomerular sclerosis in this group compared to the vehicle group (figure 30A and B). The 
glomerular structure was examined in periodic-acid Schiff (PAS) stained kidney sections 
and scored using the following criteria: 0 for normal glomerulus, 1 for mild mesangial 
expansion, 2 for moderate to severe mesangial proliferation with no sclerotic segments, 3 
for severe mesangial proliferation, partially closed capillaries and sclerotic segments and 4 
for collapsed glomerulus and total sclerosis. A minimum of 20 glomeruli were scored for 
each mouse and the evaluation was made blindly. 
 
 
 
 
 
Figure 30. Glomerular PAS score. 
A) Representative pictures of each 
group. Glomerulus presents an 
important mesangial proliferation 
and mild to severe sclerosis. B) 
Glomerular score showed no 
significant difference between 
groups. Data was analyzed with 
Man Whitney test. ns = statistically 
not significant.  
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4.3.3 Expression of p53 in db/db mice after Nutlin-3a-treatment 
As seen in previous studies and in healthy mice, p53 levels were expected to increase after 
administration of Nutlin-3a by blocking proteasomal degradation. However, in diabetic mice 
immunohistochemistry did not show a significant increase in p53 in terms of percentage of 
p53 stained area (figure 31A and B). Besides, intrarenal gene expression of p53 showed a 
significant downregulation in Nutlin-3a-treated mice compared to vehicle (figure 31C), as 
opposed to what was observed in healthy mice (see section 4.2.3 Nutlin-3a promotes Mdm2 
and p53 gene expression and increases p53 protein levels). Consistently, Mdm2 mRNA 
levels were also lower in Nutlin-3a-treated mice compared to vehicle (figure 31C). 
 
Figure 31. p53 immunostaining and gene expression of Mdm2 and p53. A) Representative pictures of p53 
immunostaining. No significant differences were seen between groups. B) Quantification of the percentage of 
stained area that shows no significant differences between the Nutlin-3a group and vehicle group. C) p53 gene 
expression is downregulated in Nutlin-3a-treated mice compared to vehicle (p<0.05), without being significant for 
Mdm2 mRNA levels. Data was analysed with Man Whitney test. ns = statistically not significant; * = p<0,05. 
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Figure 32. Gene expression of p53-tanscription dependent genes. The proapoptotic genes Bcl-2 and Bax 
are downregulated in the Nutlin-3a-treated group compared to vehicle (p<0,05) whereas mRNA levels of PUMA 
show no difference between groups. The gene expression of cyclin-dependent kinase inhibitor p21 is also 
downregulated in the Nutlin-3a-treated group compared to vehicle (p<0,05). Data was analysed with Mann 
Whitney Test. ns = statistically not significant; * = p<0,05.. 
 
Next, the expression of genes, whose transcription depends on p53, was analysed to 
further evaluate the impact of Nutlin-3a treatment on a transcriptional level. As shown in 
figure 32, the proapoptotic genes Bax and Bcl-2 and the cyclin-dependent kinase inhibitor 
p21 appeared consistently downregulated in the Nutlin-3a-treated group compared to 
vehicle, whereas PUMA showed no significant difference. 
 
 
4.3.4 Nutlin-3a-treated mice display less number of podocytes and a 
downregulation of podocyte marker gene expression 
In healthy mice, treatment with Nutlin-3a resulted in the damage of the glomerular filtration 
barrier in terms of a significant increase in proteinuria and lower podocyte count. In order to 
see whether Nutin-3a had the same effect in db/db mice with diabetic nephropathy, kidneys 
were stained for Wt1 (in red) and Nephrin (in green) (figure 33A) and the number of 
podocytes was counted in twenty different glomeruli for each kidney. As demonstrated in 
figure 33B the average of podocytes per glomerulus in Nutlin-3a-treated mice was 
significantly lower (5,84 ± 0,22) compared to vehicle-treated mice (6,59 ± 0,07).   
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To further evaluate the effect of Nutlin-3a upon podocytes in diabetic mice, mRNA levels of 
podocyte markers were quantified using RT-PCR. As represented in figure 34, mRNA levels 
of Wt-1, podocalyxin, podocin, synaptopodin, nephrin and CD2AP were significantly 
reduced in Nutlin-3a-treated mice compared to vehicle (p<0,05). 
Figure 33. Wt-1/Nephrin staining and podocyte 
count. A) Representative images of 
immunofluorescence with Wt-1/Nephrin in vehicle 
and Nutlin-3a treated group. The number of 
podocytes is considerably reduced compared to 
healthy mice due to diabetic nephropathy. B) The 
number of podocytes in the Nutin-3a treated group 
was significantly lower (5,84 ± 0,22) than in the 
vehicle group (6,59 ± 0,07). Data was analysed with 
the average of podocytes per glomerulus in each 
kidney, counting a minimum of 20 glomerules for 
each kidney. Data was analysed with Man Whitney 
test. * = p<0,05. 
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Figure 34 Gene expression of podocyte markers. mRNA levels of podocyte markers, such as nephrin, Wt-1, 
synaptopodin, podocin, Podocalyxin, and CD2AP are downregulated in the Nutlin-3a group compared to control 
and vehicle (p<0,05). Data was analysed with Mann Whitney Test. ns = statitstically not significant; * = p<0,05; 
** = p<0,01. 
 
4.3.5 Nutlin-3a attenuates renal inflammation and fibrosis diabetic mice 
Mulay and colleagues have shown that Nutlin-3a has an anti-inflammatory potential 
associated with inhibiting the p53-independent regulatory role of Mdm2 upon NFκB 
activation (Mulay SR 2012). Within this study, however, Nutlin-3a treatment in healthy mice 
displayed the opposite effect, whereby the number of infiltrating glomerular macrophages 
was higher and the intrarenal inflammatory markers were upregulated in Nutlin-3a-treated 
mice.  In order to elucidate the anti- or proinflammatory role of Nutlin-3a in diabetic mice, 
mRNA levels of inflammatory markers were screened in renal tissue of diabetic mice treated 
with Nutlin-3a or vehicle. Intrarenal mRNA expression of the NFkB subunits p50 and p65 
decreased in the Nutlin-3a-treated group compared to vehicle (p= 0,07 and 0,11, 
respectively) (figure 35C). The intrarenal mRNA expression levels of the inflammatory 
markers TNFα, CCL2, CCL5 and iNOS decreased following Nutlin-3a treatment, whereas 
the other inflammatory markers such as IL-1β, IL-6 and IL-12a did not change (figure 35D). 
Macrophage infiltration was significantly lower in Nutlin-3a-treated-mice than in the placebo 
group (figure 35A and B). This indicated that treatment with Nutlin-3a may exert anti-
inflammatory properties in db/db mice, consistent with the previous study done by Mulay et. 
al. (Mulay SR 2012). 
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Figure 35. Glomerular macrophage infiltration and gene expression of NFκB and inflammatory markers. 
A) Representative pictures of Mac2 staining for each group. B) Quantification of number of macrophages per 
glomerulus in each group. A minimum of 20 glomerules were scored for each kidney. While vehicle group 
presents an average of 2,97 ± 0,12 macrophages per glomerulus, Nutlin-3a-treated group displayed 1,81 ± 0,05 
(p<0,05). C) mRNA levels of the NFκB subunits p50 and p65 are downregulated in the Nutlin-3a-treated group 
compared to vehicle; difference is not statistically significant (p=0,07 and p=0,11, respectively). D) mRNA levels 
of inflammatory markers are not significantly reduced in the Nutlin-3a group, except for CCL5 (p<0.05). Data 
was with Mann Whitney Test. N(Vehicle) = 4; n(Nutlin-3a)=6. ns = statistically not significant; * = p<0,05.  
 
In addition, renal fibrosis in diabetic mice treated with Nutlin-3a or vehicle was analysed 
regarding the mRNA levels of fibrotic markers and collagen 1 expression. 
Immunohistochemistry of kidney sections for collagen 1 (figure 36A) showed a significant 
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lower deposition in Nutlin-3a-treated mice than in vehicle (p<0,005) in terms of percentage 
of stained area (figure 36B). Intrarenal mRNA levels of fibronectin, laminin, transforming 
growth factor beta (TGFβ), aSMA, collagen 1 subunit a1 and collagen 4 subunit a1 were 
significanly downregulated in Nutlin-3a-treated mice compared to the vehicle group (p<0,05) 
(figure 36C). 
 
 
Figure 36. Collagen 1 staining and gene expression of fibrosis markers. A) Immunohistochemistry. 
Representative pictures of collagen 1 staining of kidney sections from db/db mice treated with Nutlin-3a or 
vehicle. B) Quantification of the stained area. Nutlin-3a mice displayed a significant lower expression of collagen 
1 than the vehicle group (p<0,005). C) mRNA levels of fibronection, laminin, TGFβ, aSMA and collagen 4 a1 are 
downregulated in the Nutlin-3a-treated group compared to vehicle (p<0,05). Collagen 1, however, does not 
reach statistical significance. Data was analysed with Mann Whitney Test. ns = statistically not significant; * = 
p<0,05; ** = p<0,01. 
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5. DISCUSSION 
 
5.1 Mdm2 blockade with Nutlin-3a damages healthy renal tissue 
In resting cells, the right balance between Mdm2 and p53 is crucial to maintain proliferation 
in a controlled manner. In the kidney, where Mdm2 is mainly expressed in epithelial tubular 
cells and podocytes, deletion of Mdm2 in resting podocytes showed p53-overexpression 
dependent cell death (podoptosis) in vitro and the development of albuminuria and 
glomerulosclerosis in an in vivo model (Thomasova D. 2015). Similarly, tubular cells specific 
Mdm2 deletion in a mouse model manifested a rapid development of CKD (data not yet 
published). Hence, we hypothesized that inhibition of Mdm2 with Nutlin-3a damages renal 
function by promoting podoptosis in podocytes and tubular cells.  
 
To test our hypothesis, cultured mouse podocytes and mouse tubular cells were stimulated 
with Nultin-3a in three different doses and the viability and cytotoxicity in two different time 
points was then measured. As hypothesized, the culture of immortalized mouse podocytes 
and mouse tubular cells with Nutlin-3a prompted cell death and decreased viability in a 
dose-dependent manner, showing that the blockade of Mdm2 with the drug can certainly 
affect healthy cells, as it has been previously shown in siRNA experiments (Thomasova D. 
2015). This result seems to contradict the work of Jiang et al., where they showed that the 
administration of Nutlin-3 was not toxic to normal cultured tubular cells. However, Nutlin-3 
represents a mixture of the active enantiomer 3a and the inactive 3b (Vassilev 2004); that 
means that the employed concentrations of Nutlin-3 might not have been sufficient to reach 
the efficiency of the full active Nutlin-3a. Furthermore, toxicity was evaluated in terms of 
apoptosis, assessing cell morphology and caspase activation (Jiang 2007). Thus, the lack 
of caspase activity rather than proving no toxicity, further supports an alternative caspase-
independent cell death, i.e. podoptosis.  
 
In light of the results in vitro, systemic injections of Nutlin-3a during one month were given 
to healthy mice to monitor renal function. Although the renal function, in terms of plasma 
creatinine levels, was not significantly affected, blood urea nitrogen levels were significantly 
higher and the urine albumin/creatinine ratio increased progressively in the treated group 
reaching significance at the end of the study. Consistently, the number of podocytes was 
significantly lower in this group.  
Discussion  
75  
In addition, body weight was observed to decrease in contrast to control groups, which 
progressively increased weight with age. This observation was already made by Mendrysa 
et al., who generated mice that possessed a hypomorphic allele expressing approximately 
30% of the total Mdm2 levels. These mice not only had decreased body weight, like in the 
present study, but displayed defects in haematopoiesis and were more radiosensitive than 
normal mice (Mendrysa SM 2003). This translates a lower capacity to respond to injury and 
to proliferate. Hence, small insults in renal tissue (and other tissues as well) might affect the 
kidney in a greater way when Mdm2 is blocked than under normal conditions. In fact, mice 
treated with Nutlin-3a not only manifested an incipient defect in the glomerular filtration 
barrier, but presented upregulation of tubular injury markers, inflammatory markers and 
increased glomerular macrophage infiltration. In the previous studies by Mulay et al., Nutlin-
3a attenuated inflammation during acute kidney injury and rapid progressive 
glomerulonephritis (Mulay SR 2012, Mulay SR 2016), whereas under healthy conditions the 
opposite was now observed. It is therefore possible that Mdm2 has a dual role upon NFkB 
activation, as described by Cheney in transformed cells (Cheney MD 2008). 
 
The findings of the present study confirm that inhibition of Mdm2 with Nutlin-3a damages 
podocytes and tubular cells, hence impairing the glomerular filtration barrier and renal 
function. The higher expression of p53 in renal tissue and the upregulation of its target 
genes, such as Mdm2, p21, Bax and Bcl-2, point towards podoptosis as the mechanism of 
podocytopenia. It is noteworthy to mention that the gene expression of p53 upregulated 
modulator of apoptosis (PUMA), a pro-apoptotic gene induced by p53 that belongs to the 
Bcl-2 family, appeared unchanged. This observation was consistent with the findings by 
Jiang et al. (Jiang 2007), and further supports podoptosis as a specific type of regulated cell 
death and not apoptosis.  
 
 
5.2 Nutlin-3a affects the outcome of diabetic nephropathy in db/db mice in opposite 
ways 
Nutlin-3a attenuates inflammation and fibrosis 
Given that in an inflammatory milieu Mdm2 has been shown to promote the NFκB pathway 
in a p53-independent manner (Mulay SR 2012, Mulay SR 2016) and that diabetic disease is 
characterized by chronic inflammation, partly promoted by the activation of the NFκB 
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pathway (Schmid H 2006, Sanchez AP 2009), we hypothesized that Nutlin-3a would 
ameliorate diabetic kidney disease by attenuating chronic inflammation. Indeed, reduced 
inflammation was observed in Nutlin-3a-treated mice, which presented less glomerular 
macrophage infiltration, downregulation of fibrotic markers and less collagen deposition.  
 
Nutlin-3a aggravates podocytopenia in db/db mice 
By means of an adriamycin nephropathy model with BALB/c mice, a model for focal 
segmental glomerulosclerosis (FSGS), Mulay et al. showed how Mdm2 drives podocytes 
under stress into mitotic catastrophe, leading to increased cell death. Blocking Mdm2 with 
Nutlin-3a ameliorated the disease in this model by preventing mitotic catastrophe and 
allowing podocytes to remain arrested and to undergo hypertrophy (Mulay SR 2013). Given 
that podocyte loss is a major and early event in diabetic nephropathy and that hypertrophy 
of these cells has also been described in the course of the disease (Hoshi S. 2002, 
Petermann AT 2005), we hypothesized that blocking Mdm2 with Nutlin-3a in diabetic 
nephropathy would slow down the progression of the disease by protecting podocytes from 
mitotic catastrophe.  
 
Cell culture of mouse podocytes in a high glucose media did however not show a protective 
role from Nutlin-3a. Yet these results have to be interpreted rather carefully, since 
hyperglycaemia per se did not induce podocyte death as described in the literature (Susztak 
K 2006, Eid AA 2009, Ma T 2013). Tubular cell death in a diabetic milieu has likewise been 
reported previously (Allen DA 2003, Verzola D 2004, Habib SL 2013), but was not observed 
in this study. 
 
Nevertheless, the results in vivo supported those in vitro: Nutlin-3a-treated mice displayed a 
lower number of podocytes and lower gene expression of podocyte markers after Mdm2 
inhibition. This observation revealed that Nutlin-3a induces podocytopenia in this diabetic 
nephropathy mouse model rather than having a protective effect. Therefore, this outcome 
strongly argues for mitotic catastrophe being a mechanism of podocyte death in this study. 
In fact, more types of cell death other than mitotic catastrophe have been described in 
podocytes (figure 37), including apoptosis (P Mundel 1997, Schiffer M. 2001, Ryu M 2012) 
and podoptosis (M Ebrahim 2015, Thomasova D. 2015). In both types of cell death, p53 is 
overexpressed and drives programmed cell death. The first being a caspase-dependent 
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type of cell death, whereas in podoptosis caspases are not involved (Thomasova D. 2015). 
Owing to the fact that Nutlin-3a inhibits Mdm2 negative regulation of p53 and promotes its 
stabilization, the idea of any of these two pathways being the cause of podocytopenia in this 
study is surely plausible. However, p53 immunostaining did not show an increase of p53 
expression in the glomeruli in the Nutlin-3a-treated group. In addition, the transcription of 
genes promoted by p53 was downregulated. It remains therefore unclear, through which 
pathway injured podocytes died or detached from the glomerular barrier membrane (GBM) 
in this model of diabetic nephropathy, thus causing podocytopenia.  
 
Figure 37. Causes of podocytopenia. The mechanisms underlying podocytopenia are still being elucidated. It 
has been shown that after injury, podocytes can undergo apoptosis as a result of increased transforming growth 
factor beta (TGFβ), angiotensin II (ANGII) and tumour necrosis factor α (TNFα). Podoptosis has also been 
described as a caspase-independent form of cell death ascribed to low levels of Mdm2 and consequent 
overexpression of p53. After podocyte injury, cells can also undergo cell cycle arrest and hypertrophy through 
upregulation of the cyclin-dependent kinase inhibitors (CDKI) p21 and p27. This response compensates shortly 
podocyte loss but can be truncated, if Mdm2 levels raise and mitosis is promoted; leading to an aberrant mitosis 
and eventually cell death (mitotic catastrophe). Detachment of viable podocytes has been also described after 
injury, but the underlying mechanisms are not known. Adapted from (Mundel P 2002). 
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The opposite effect of Nutlin-3a upon db/db mice, where on one hand podocytes damage 
and loss is induced and on the other hand inflammation is attenuated, could possibly 
explain why the histological structure was not significantly different between groups. Yet, 
the overall renal function was in terms of BUN significantly aggravated in Nutlin-3a-treated 
mice compared to vehicle, possibly due to the increased podocytopenia and tubular 
damage.  
 
The worsening of DKD in this model could also be explained by an extra role of Mdm2 in 
diabetic disease. Saito and colleagues recently revealed by means of a computational 
network associating data from metabolomic analysis (MetabPPI) that Mdm2 presents a 
significant high number of interactions with enzymes associated with metabolites that are 
altered in DKD (Saito R 2016). The relevance of Mdm2 was further proved in two 
independent human cohorts, in which mRNA levels of Mdm2 appeared downregulated in 
both glomeruli and tubules. Still it is not known yet, by which means Mdm2 is 
downregulated and whether this molecular modification has an important association with 
the pathophysiology of DKD or it is rather a consequence of one or more activated 
pathways. This study could however explain why the administration of Nutlin-3a in healthy 
mice features some pathological marks of DKD, such as albuminuria and mesangial 
expansion (figure 19A).  
 
In summary the results observed in diabetic mice treated with Nutlin-3a showed that the 
blockade of Mdm2 prompts aggravation of podocytopenia and renal function and, at the 
same time, attenuates renal inflammation and fibrosis. Together, these results reveal a 
deleterious effect of Mdm2 blockade upon podocytes in healthy mice as well as in a DKD 
model, in contrast to acute kidney injury models. At the same time, an advantageous effect 
upon inflammation through inhibition of the NF-κB pathway was observed. A direct inhibition 
of NF-κB, for example with celastrol, could therefore offer a novel therapeutic strategy in 
DKD without a negative effect upon podocyte loss, as shown by Kim et al in a db/db mouse 
model (Kim JE 2013). In addition, further research on Mdm2 and its role in DKD could 
contribute to the better understanding of its complex pathophisiology and thereby to its 
treatment. 
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5.3 Limitations of the study and future perspectives 
The present study includes however certain limitations. An important hindrance was the use 
of a mouse model to study the human DKD. As commented above, this always results in a 
big constraint to infer conclusions of the disease in humans, since this model (like other 
diabetic mouse models) cannot fully resemble the disease. As a consequence, the study 
displays a very restricted external validity. The role of the activated RAAS system and the 
consequent systemic hypertension is for both T1D and T2D, though in different extent, a 
hallmark and important factor of the DKD progression. However, the db/db mouse model 
presents low blood pressure, as opposed to humans. To closely resemble human diabetic 
features from T2D, the db/db diabetic model was stressed with both uninephrectomy and 
high fat diet; this caused high mortality, resulting in a much reduced group size that 
presented high variability. For that reason and the above mentioned, a new study is 
intended with different diabetic models that will complement the results of the present one 
and offer a wider interpretation.  
 
The evaluation of renal function was indirectly measured in terms of BUN and serum 
creatinine. Despite being these two parameters orientative for the GFR, other methods have 
been proved more precise, for example inulin-clearance. Additionally, a more meticulous 
analysis on the effect of Nutlin-3a on the tubular compartment should be performed, since 
this work focused mainly on the glomeruli.  
 
In vitro studies were also limited by the use of mouse cell lines instead of primary cells. 
Besides, a more detailed study on the gene and protein expression alterations after Nutlin-
3a stimulation would render more information on the molecular pathways that are modified 
and how these may affect tissue function.  
 
5.4 Conclusions 
In brief, therapeutic blockade of Mdm2 with Nutlin-3a may hold the risk of increased 
podocyte and tubular cell death within the kidney. While tubular epithelium has a high 
potential of renewal, the regeneration of podocytes is limited and might affect the glomerular 
filtration barrier function and eventually cause impaired renal function. In diabetic kidney 
disease, where these two compartments are already impaired, Nutlin-3a can further 
aggravate the disease. 
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ABBREVIATIONS 
 
A 
ACTA1  Actin alpha 1 
AGE/RAGE  Advanced Glycation Endproduct / Receptors of AGE 
AKI   Acute kidney injury 
ANGII   Angiotensin II 
aSMA   Actin, alpha skeletal muscle 
 
B 
Bcl-2   B-cell Lymphoma 2 
BUN    Blood Urea Nitrogen 
 
C 
CCL x   Chemokine Ligand x 
CCR x   Chemokine Receptor x 
CD2AP  CD2 associated protein 
CKD   Chronic kidney disease 
Col 1/4  Collagen 1/4 
 
D 
db/db   Leptin receptor deficient mice 
DKD   Diabetic kidney disease 
DM   Diabetes mellitus 
DMSO   Dimethyl-sulfoxide 
DNA   Desoxyribonucleic acid 
 
E 
ESRD   End stage renal disease 
 
F 
FSGS   Focal segmental glomerulosclerosis 
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G 
GFB   Glomerular filtration barrier 
GFR   Glomerular filtration rate 
GS   Glomerular score 
 
H 
HDL   High density lipoprotein 
 
I 
ICAM x  Intercellular adhesion molecule 
IL x   Interleukine x 
iNOS   Inducible nitric oxide synthase 
i.p.   intraperitoneal 
 
J 
JAK/STAT  Janus kinase / Signal transducers and activators of transcription 
 
L 
LDH   Lactate dehydrogenase 
LDL   Low density lipoprotein 
 
M 
Mdm2   Murine double minute 2 
MTC   Mouse tubular cells 
mRNA   Messenger RNA 
 
N 
NF-κB   Nucear factor ‘kappa light chain enhancer’ of activated Bcells 
 
P 
PAS   Periodic Acid Schiff 
PCR   Polymerase chain reaction 
PEC   Parietal epithelial cells 
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PKC   Proteinkinase C 
PUMA   p53 upregulator of apoptosis 
 
R 
RAAS   Renin Angiotensin Aldosterone System 
RITA   Reactivation of p53 and induction of tumour cell apoptosis 
RNA   Ribonucleic acid 
ROS   Reactive oxygen species 
RT-PCR  Real time PCR 
 
S 
SGLT 1/2   Sodium glucose transporter 1/2   
SNGFR  Single nephron GFR 
siRNA   Small interfering RNA 
 
T 
T1/2D   Type 1/2 Diabetes 
TGF   Tubuloglomerular feedback 
TGFβ   Transforming growth factor beta 
TNFα   Tumour necrosis factor alpha 
 
V 
VEGF   Vascular endothelial growth factor 
 
W 
WT1   Wilms tumour 1 
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Table 1. Severity of kidney disease. GFR = glomerular filtration rate; ESRD = End-stage 
renal disease. Adopted from (Levey AS 2005) 
 
Table 2. Classification of diabetes types. Adapted from (Powers 2008). 
 
Table 3. Manifestations of the db/db mouse model and its similarities and differences 
with human T2DM features. Adapted from (Wang B. 2014). 
 
Table 4. High fat diet composition. Composition of the high fat diet (%), which was used 
to feed mice within the study. 
 
Table 5. Comparison between regular and high fat diet. ME = metabolizable energy. 
 
Table 6. PAS glomerular score criterion.  
 
Table 7. Primer sequences used in this study. Abbreviations: Bcl-2 = B-Cell lymphoma 2, 
PUMA = p53 upregulator of apoptosis, Wt1 = wilms tumour protein 1, CD2AP = CD2 
associated protein, RANTES = regulated on activation, normal T cell expressed and 
secreted, TNFα = tumour necrosis factor α, iNOS = inducible nitric oxide synthase, aSMA = 
actin, alpha skeletal muscle, ACTA1 = actin alpha 1, Col1/4 = collagen type ¼, TGFβ = 
transforming growth factor beta. 
 
Figure 1. Prognosis of CKD by GFR and albuminuria categories. The colours represent 
the intensities of risk. Green: low risk; yellow: moderately increased risk; orange: high risk; 
red: very high risk. Adapted from (KDIGO 2012). 
 
Figure 2. Hyperglycaemia and deactivation of the tubuloglomerular feedback (TGF). 
The increased reabsortion of glucose in the proximal tubule under hyperglycaemic 
conditions implies an increased reabsortion of sodium and therefore a reduced 
concentration of sodium in the distal tubule and the macula densa. This causes a release of 
renin from juxtaglomerular cells and a consequent activation of RAAS, which provokes 
efferent vasoconstriction and a higher glomerular pressure as well as higher SNGFR. 
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SGLT2 = sodium glucose cotransporter-2, RAAS = Renin Angiotensin Aldosterone System, 
SNGFR= Single-Nephron glomerular filtration rate.  
 
Figure 3. Schematic drawing of the glomerular filtration barrier, composed of 
podocytes and its pseudopods, the glomerular basement membrane (GBM) and the 
endothelium. Adapted from (Haraldsson B. 2008).  
 
Figure 4. Autorregulatory feedback loop. In conditions of no stress, Mdm2 inhibits p53 in 
three ways: 1) blocks transactivation of p53, 2) favours nuclear export, and 3) induces p53 
degradation. However, upon DNA damage, p53 levels increase and transactivation of p53 
targets takes place. Among p53 target genes, there is Mdm2. If the DNA damage is 
repaired, the increasing levels of Mdm2 will again inhibit p53 and restore its levels. Adapted 
from (Chène 2003).  
 
Figure 5. Mdm2 protein domains. The conserved domains of Mdm2 are the p53 
interaction domain in the aminoterminus, the nuclear localization signal (NLS) and the 
nuclear export signal (NES), the acidic domain and Zinc finger, which interact with 
ribosomal proteins, and in the carboxiterminus the RING finger domain with E3 ubiquitin 
ligase activity. Adapted from (Iwakuma T 2003). 
 
Figure 6. p53 stabilization and response. In non-stressed cells, p53 exists in very low 
concentrations. Under cellular stress, the levels of p53 raise and p53 mediates the 
transcription of genes involved in apoptosis, cell cycle arrest, and DNA repair. Adapted from 
(Chène 2003).  
 
Figure 7. Inhibitors of the Mdm2-p53 interaction. Schematic representation of the Mdm2 
and p53 proteins. Nutlin binds Mdm2 in the p53 binding domain in the aminoterminus, 
HLI98 binds Mdm2 in the RING domain, and RITA binds p53 in the transactivation domain.  
Adapted from (Marine JC 2010). 
 
Figure 8. Immunofluorescence staining for Nephrin and Mdm2 of a glomerulus. In the 
first picture on the left, nephrin stains in green the cytoplasm of podocytes. In the second 
one, expression of Mdm2 inside the glomerulus is stained in red. In the last picture, on the 
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right, merged colours show how the localisation of nephrin coincide with that of Mdm2. 
Picture ceded by Dr. Thomasova. 
 
Figure 9. Schematic diaphragm of podocytopathies and mitotic catastrophe. Podocyte 
stress activates podocytes to undergo hypertrophy to compensate podocytopenia. 
Hypertrophy takes place because of p53-mediated induction of cyclin kinases such as p21, 
which arrest cell cycle in the G1 restriction point. Mdm2 inactivates p53 and its targets and 
drives the podocyte to complete (aberrant) mitosis, resulting in bi- or multinucleated 
podocytes. As a consequence, aneuploid podocytes undergo immediately cell death and 
detach from the GFB or remain for some time in the GFB and then die. Adapted from (L 
Lasagni 2013). 
 
Figure 10. Experimental time line of the animal study.  
 
Figure 11. Incision site. Left kidney is localized slightly medial and caudal from the spleen. 
The triangle delimited by the end of the rib cage and the vertebral column defines the area 
to operate.  
 
Figure 12. Viability (MTT assay) and cytotoxicity (LDH assay) in mouse podocytes. A) 
Stimulation with Nutlin-3a significantly reduced podocyte viability after 12 hours of 
stimulation compared to control. The difference with the vehicle however showed no 
significance. B) After 24 hours, this difference between Nutlin3a and vehicle becomes 
statistically significant (p<0,0005). C-D) Cytotoxicity also increased significantly with Nutlin-
3a compared to control and vehicle in a dose-dependent manner. Triton X was used as 
negative control in the viability assay and as positive control and reference for the 
cytotoxicity assay. On the other hand, podocytes cultured in media with 5% serum 
represented the survival control. n=5 for each group. Data was analysed using 1-way 
ANOVA with Tukey’s Multiple Comparison Test. NG = normal glucose media (11mM); 
NG+10 = normal glucose media with 10µM of Nutlin-3a; NG+15 = normal glucose media 
with 15µM of Nutlin-3a; NG+20 = normal glucose media with 20µM of Nutlin-3a; NG+DMSO 
= normal glucose with 20µl/ml of DMSO. * = p<0,05; ** = p<0,005; *** = p<0,0005. 
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Figure 13. A-B) Viability (MTT assay) and C-D) cytotoxicity (LDH assay) in mouse 
tubular cells. A) Stimulation with Nutlin-3a reduced tubular cell viability after 12 hours and 
B) after 24 hours post-stimulation compared to control and vehicle, being statistically 
significant at the later time point. C-D) Nutlin-3a stimulation increased significantly 
cytotoxicity in a dose-dependent manner after 6 and 24 hours. Triton X was used as 
negative control for the MTT assay and as positive control and reference for the cytotoxicity 
assay. Podocytes cultured in media with 5% serum served as survival control. n = 5 for 
each group. NG = normal glucose media (5,5mM); NG+10 = normal glucose media with 
10µM of Nutlin-3a; NG+15 = normal glucose media with 15µM of Nutlin-3a; NG+20 = 
normal glucose media with 20µM of Nutlin-3a; NG+DMSO = normal glucose with 20µl/ml of 
DMSO. Data was analyzed using 1-way ANOVA with Tukey’s Multiple Comparison Test. * = 
p<0,05; ** = p<0,005; *** = p<0,0005. 
 
Figure 14. Viability (MTT assay) and cytotoxicity (LDH assay) in mouse podocytes 
and mouse tubular cells exposed to normal (5,5-11mM) or high glucose media 
(45mM). A) An environment rich in glucose increases mouse podocyte viability and reduces 
significantly cell death after 48 hours. B) Mouse tubular cells presented by contrast no 
statistical difference in viability but again they did in cytotoxicity in the later time point, being 
significantly greater in a normal glucose than in high glucose media. Data was analyzed 
with t-test.n = 10 in each group. NG = normal glucose media (5-10mM); HG = high glucose 
media (25mM). * = p<0,05; ** = p<0,005; *** = p<0,0005. 
 
Figure 15. Viability (MTT assay) and cytotoxicity (LDH assay) in mouse podocytes 
cultured in high glucose media (45mM). A) Podocyte stimulation with Nutlin-3a in a high 
glucose media reduces significantly cell viability in a dose-dependent manner compared to 
control after 12 hours and B) after 24 hours, which was significantly different compared to 
vehicle. C-D) Nutlin-3a stimulation in podocytes exposed to high glucose media increases 
significantly the cytotoxicity  in a dose-dependent manner compared to control and vehicle 
after 6 and 24 hours. Triton X was used as negative control in the viability assay and as 
positive control and reference for the cytotoxicity assay. Manitol (25mM) was used as 
control of osmolarity for the high glucose environment. No statistical differences were found 
between manitol and high glucose that could suggest a negative effect of high glucose 
media in cell osmolarity. Data was analyzed with 1 way ANOVA withTukey’s Multiple 
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Comparison Test. n = 5 per group. HG = high glucose media; HG+10 = high glucose media 
with 10µM of Nutlin-3a; HG+15 = high glucose media with 15µM of Nutlin-3a; HG+20 = high 
glucose media with 20µM of Nutlin-3a; HG+DMSO = high glucose with 20µl/ml of DMSO. * 
= p<0,05; ** = p<0,005; *** = p<0,0005. 
 
Figure 16. Viability (MTT assay) and cytotoxicity (LDH assay) in mouse tubular cells 
cultured in high glucose media (45mM). A) Stimulation of mouse tubular cells with Nutlin-
3a of exposed to high glucose media reduced significantly the cell viability in a dose-
dependent manner compared to control after 12 hours. B) After 24 hours, viability was also 
significantly reduced after Nutlin-3a stimulation compared to control but not to vehicle. C) 
Cytotoxicity in MTCs exposed to high glucose media increased in the Nutlin-3a-treated 
groups compared to control after 6 hours, but the difference was not significant compared to 
vehicle. D) After 24 hours of stimulation with Nutlin-3a no significant differences were seen 
among the groups. Triton X was used as negative control in the viability assay, and as 
positive control and reference for the cytotoxicity assay. Manitol (25mM) was used as 
control of osmolarity for the high glucose environment. No statistical differences were found 
between manitol and high glucose that could suggest a negative effect of high glucose 
meda in cell osmolarity. Data was analyzed with 1-way ANOVA with Tukey’s Multiple 
Comparison Test. n = 5 per group. HG = high glucose media; HG+10 = high glucose media 
with 10µM of Nutlin-3a; HG+15 = high glucose media with 15µM of Nutlin-3a; HG+20 = high 
glucose media with 20µM of Nutlin-3a; HG+DMSO = high glucose with 20µl/ml of DMSO. * 
= p<0,05; ** = p<0,005; *** = p<0,0005.  
 
Figure 17. Body weight, blood glucose levels and survival percentage. A) Body weight 
monitoring during treatment with Nutlin-3a. While body weight in vehicle and control mice 
increased progressively with age, Nutlin-3a-treated mice lost weight from the moment that 
the treatment was established. B) At the end of the study, the body weight of Nutlin-3a-
treated mice was significantly lower compared to control and vehicle (p<0.0005). C) 100% 
of control (n=3) and vehicle (n=6) mice survived until the end of the study while only 72% of 
Nutlin-3a-treated mice did (n=11). The difference is however no significant (p=0.2). Survival 
curves were compared with Mantel-Cox test. D) Glycaemia at the end of the study was 
significantly lower in Nutlin-3a-treated mice compared to vehicle (p<0.05) but not compared 
to control mice (p>0.05). 
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Figure 18. Renal functional parameters. A) Plasma creatinine levels increased in the 
Nutlin-3a group (2.8 ± 1.4 mg/dl) compared to vehicle and control (1.8 ± 0.7 and 1.7 ± 0.6 
mg/dl, respectively), but not significantly. B) Blood urea nitrogen (BUN) levels at the end of 
the study significantly increased in Nutlin-3a-treated group (36.2 ± 3.6 mg/dl) compared to 
vehicle (23.9 ± 3.2 mg/dl) (p<0,05), but not to control (26.7 ± 1.7 mg/dl). C-D) 
Albumin/creatinine ratio increased slightly after the first week of treatment and strikingly at 
the end of the treatment, being significantly higher compared to vehicle and control 
(p<0.05). Data were analysed with 1-way ANOVA with Tukey’s Multiple Comparison Test. 
n(Control) = 3; n(Vehicle) = 6; n(Nutlin-3a) = 5. ns = statistically not significant; * = p<0,05. 
 
Figure 19. Glomerular PAS score and mRNA expression. A) Representative pictures of 
each group. Original magnification 40x. (Arrow: mild mesangial expansion). B) 
Semiquantification of glomerular damage in PAS stained slides of paraffin-fixed kidney 
tissue. While control and vehicle mice have an average of 0.11±0.05 and 0.20±0.13, being 
0 considered as normal and 1 as mild mesangial proliferation, Nutlin-3a-treated mice 
present a significant higher score with an average of 0.50±0.14. C) Gene expression of 
tubular injury markers appear upregulated in Nutlin-3a mice. Data was analysed with 1 way 
ANOVA with Tukey’s Multiple Comparison Test. n(Control) = 3; n(Vehicle) = 6; n(Nutlin-3a) 
= 5. ns = statistically not significant; * = p<0,05. 
 
Figure 20. p53 immunostaining and gene expression of MDM2 and p53. A) 
Representative pictures of p53 immunostaining. In the Nutlin-3a group, overexpression of 
p53 in the periphery of the glomeruli and in some tubular cells was seen, as shown in the 
picture (white arrow), whereas no p53 staining was observed in vehicle and control treated 
mice. B) Quantification of the percentage of stained area that shows significantly higher p53 
levels in the Nutlin-3a group compared to vehicle (p<0,05). C) Both Mdm2 and p53 
expression is upregulated in Nutlin-3a-treated mice compared to control and vehicle 
(p<0.05). Data was analysed with 1 way ANOVA with Tukey’s Multiple Comparison test. ns 
= statistically not significant; * = p<0,05; ** = p<0,005. 
 
Figure 21. Gene expression of p53-related target genes. The pro-apoptotic genes Bcl-2 
and Bax are upregulated in the Nutlin-3a group compared to vehicle and control (p<0,05), 
List of figures and tables  
110  
whereas mRNA levels of PUMA did not differ between groups. The gene expression of 
cyclin-dependent kinase inhibitor p21 is also upregulated in the Nutlin-3a-treated group 
compared to vehicle (p<0,05), but not to control. Data was analysed with 1-way ANOVA 
with Tukey’s Multiple Comparison Test. ns = statistically not significant; * = p<0,05; ** = 
p<0,005. 
 
Figure 22. Wt-1/Nephrin staining and podocyte count. A) Representative pictures of 
each group. In red, Wt1; in green, Nephrin. B) Quantification. The number of podocytes in 
the Nutin-3a-treated group was significantly lower (11,55 ± 0,48) than the one in the vehicle 
group (13,66 ± 0,68) and control group (15,87 ± 0,35). Data was analysed with the average 
of podocytes per glomerulus in each kidney, involving a minimum of 20 glomeruli for each 
kidney. 1-way ANOVA with Tukey’s Multiple Comparison Test was applied. ns = statistically 
not significant; * = p<0,05; ** = p<0,005.  
 
Figure 23. Gene expression of NFκB and inflammatory markers. A) mRNA levels of the 
NFκB subunits, p50 and p65, appear significantly upregulated in the Nutlin-3a-treated group 
compared to control and vehicle (p<0,05). B) mRNA levels of CCL5, CCL2, IL-1β, TNFα, 
iNOS, IL-12a and IL-6 are significantly upregulated in Nutlin-3a-treated mice compared to 
vehicle (p<0.05). Data was analysed with 1-way ANOVA with Tukey’s Multiple Comparison 
Test. ns = statistically not significant; * = p<0,05; ** = p<0,005. 
 
Figure 24. Glomerular macrophage infiltration. A) Representative pictures of Mac2 
staining of kidney sections from vehicle and Nutlin-3a-treated mice. Arrows point at stained 
macrophages. B) Quantification. The average number of macrophages in the Nutlin-3a-
treated group (0,98 ± 0,11) is significantly higher than that observed in the vehicle group 
(0,57 ± 0,11) (p<0,05). The difference however with the control group (0,61 ± 0,13) is not 
statistically significant. On the left a picture of a representative glomerulus for the vehicle 
and Nutlin—3a group is displayed. Arrows point at stained macrophages. Data was 
analysed with 1-way ANOVA with Tukey’s Multiple Comparison Test. ns = statistically not 
significant; * = p<0,05.. 
 
Figure 25. Gene expression of fibrosis markers. There are no significant differences 
between groups in the gene expression of fibrotic markers such as Fibronectin, aSMA, 
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Col1a1 and Coll4a1. However, expression of Laminin (p<0,05) and TGFβ (p<0,05) are 
significantly upregulated compared to vehicle and control. Data was analysed with 1-way 
ANOVA with Tukey’s Multiple Comparison Test. ns = statistically not significant; * = p<0,05; 
** = p<0,005 
 
Figure 26. Collagen 1 immunohistochemistry. A) Representative pictures of collagen 1 
staining for each group. No significant differences were observed between groups. Pictures 
were analysed with Image J. B) Quantification of the percentage of stained area. Data was 
analyzed using 1 way ANOVA and Tukey’s Multiple Comparison Test. ns = statistically not 
significant.  
 
Figure 27. Percentage of survival and glycaemia. A) In both groups, mortality during the 
treatment was very high but no significant differences were seen between survival rates. B) 
Plasma glucose levels were steadily high in both groups, and no significant difference was 
observed between groups. Survival curves were compared with Mantel Cox Test and 
glycaemia was analysed with 2-Way-ANOVA. 
 
Figure 28. Cholesterolemia and triacylgliceridemia. A high fat diet (10% fat content) was 
employed in the study, to emulate closer the human environmental factors of diabetes type 
II. As a control, blood of diabetic mice with the same background and age, which also 
underwent uninephrectomy, was concurrently analysed with a colorimetric assay. A) 
Triacylgliceride levels increased significantly over time (p<0,0001) but were not affected by 
a diet richer in fat content (p=0,36); however, B) cholesterolemia was significantly higher in 
these mice than in those fed with a normal diet (p<0,0001) . Data were analysed with 2-
Way-ANOVA. UNI = uninephrectomized; ND = normal diet (4,5% fat content); HFD = high 
fat diet (10% fat content); ns = statistically not significant; * = p<0,05; ** = p<0,005; *** = 
p<0,0005.  
 
Figure 29. Renal functional parameters. A) Plasma creatinine levels are increased in 
Nutlin-3a group (2.10 ± 0.23 mg/dl) compared to vehicle (1.33 ± 0.06 mg/dl), but not 
significantly (p=0,09). B) Blood urea nitrogen (BUN) levels increased overtime, being 
significantly higher after four weeks of treatment with Nutlin-3a (p<0,05).. C-D) Albuminuria 
as means of albumin/creatinine ratio appeared not significantly different between groups. 
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Data was analysed with Man Whitney Test for A and D, and with 2-Way-ANOVA for B. 
n(Vehicle) = 4, n(Nutlin-3a) = 6.  ns = statistically not significant; * = p<0,05 
 
Figure 30. Glomerular PAS score. A) Representative pictures of each group. Glomerulus 
presents an important mesangial proliferation and mild to severe sclerosis. B) Glomerular 
score showed no significant difference between groups. Data was analyzed with Man 
Whitney test. ns = statistically not significant.  
 
Figure 31. p53 immunostaining and gene expression of Mdm2 and p53. A) 
Representative pictures of p53 immunostaining. No significant differences were seen 
between groups. B) Quantification of the percentage of stained area that shows no 
significant differences between the Nutlin-3a group and vehicle group. C) p53 gene 
expression is downregulated in Nutlin-3a-treated mice compared to vehicle (p<0.05), 
without being significant for Mdm2 mRNA levels. Data was analysed with Man Whitney test. 
ns = statistically not significant; * = p<0,05. 
 
Figure 32. Gene expression of p53-tanscription dependent genes. The proapoptotic 
genes Bcl-2 and Bax are downregulated in the Nutlin-3a-treated group compared to vehicle 
(p<0,05) whereas mRNA levels of PUMA show no difference between groups. The gene 
expression of cyclin-dependent kinase inhibitor p21 is also downregulated in the Nutlin-3a-
treated group compared to vehicle (p<0,05). Data was analysed with Mann Whitney Test. 
ns = statistically not significant; * = p<0,05.. 
 
Figure 33. Wt-1/Nephrin staining and podocyte count. A) Representative images of 
immunofluorescence with Wt-1/Nephrin in vehicle and Nutlin-3a-treated group. The number 
of podocytes is considerably reduced compared to healthy mice due to diabetic 
nephropathy. B) The number of podocytes in the Nutin-3a treated group was significantly 
lower (5,84 ± 0,22) than in the vehicle group (6,59 ± 0,07). Data was analysed with the 
average of podocytes per glomerulus in each kidney, counting a minimum of 20 glomerules 
for each kidney. Data was analysed with Man Whitney test. * = p<0,05. 
 
Figure 34. Gene expression of podocyte markers. mRNA levels of podocyte markers, 
such as nephrin, Wt-1, synaptopodin, podocin, Podocalyxin, and CD2AP are downregulated 
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in the Nutlin-3a group compared to control and vehicle (p<0,05). Data was analysed with 
Mann Whitney Test. ns = statitstically not significant; * = p<0,05; ** = p<0,01. 
 
Figure 35. Glomerular macrophage infiltration and gene expression of NFκB and 
inflammatory markers. A) Representative pictures of Mac2 staining for each group. B) 
Quantification of number of macrophages per glomerulus in each group. A minimum of 20 
glomerules were scored for each kidney. While vehicle group presents an average of 2,97 ± 
0,12 macrophages per glomerulus, Nutlin-3a-treated group displayed 1,81 ± 0,05 (p<0,05). 
C) mRNA levels of the NFκB subunits p50 and p65 are downregulated in the Nutlin-3a-
treated group compared to vehicle; difference is not statistically significant (p=0,07 and 
p=0,11, respectively). D) mRNA levels of inflammatory markers are not significantly reduced 
in the Nutlin-3a group, except for CCL5 (p<0.05). Data was with Mann Whitney Test. 
N(Vehicle) = 4; n(Nutlin-3a)=6. ns = statistically not significant; * = p<0,05.  
 
Figure 36. Collagen 1 staining and gene expression of fibrosis markers. A) 
Immunohistochemistry. Representative pictures of collagen 1 staining of kidney sections 
from db/db mice treated with Nutlin-3a or vehicle. B) Quantification of the stained area. 
Nutlin-3a mice displayed a significant lower expression of collagen 1 than the vehicle group 
(p<0,005). C) mRNA levels of fibronection, laminin, TGFβ, aSMA and collagen 4 a1 are 
downregulated in the Nutlin-3a-treated group compared to vehicle (p<0,05). Collagen 1, 
however, does not reach statistical significance. Data was analysed with Mann Whitney 
Test. ns = statistically not significant; * = p<0,05; ** = p<0,01.  
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